10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the quarterly period ended March 31, 2016

OR

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from               to               

Commission File Number 1-7293

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)

Nevada (State of Incorporation) 95-2557091 (IRS Employer Identification No.)

1445 Ross Avenue, Suite 1400
Dallas, TX 75202

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.   Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Exchange Act Rule 12b-2).

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).  Yes ☐ No ☒

At April 27, 2016, there were 99,304,410 shares of the Registrant’s common stock, $0.05 par value, outstanding.

TENET HEALTHCARE CORPORATION

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Financial Statements	1
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	51
Item 4.	Controls and Procedures	51
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	52
Item 1A.	Risk Factors	52
Item 6.	Exhibits	52

i

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

Dollars in Millions

(Unaudited)

	March 31,		December 31,
	2016		2015
ASSETS
Current assets:
Cash and cash equivalents	$	728	$	356
Accounts receivable, less allowance for doubtful accounts ($901 at March 31, 2016 and $887 at December 31, 2015)		2,807		2,704
Inventories of supplies, at cost		312		309
Income tax receivable		—		7
Assets held for sale		2		550
Other current assets		1,280		1,245
Total current assets		5,129		5,171
Investments and other assets		1,142		1,175
Deferred income taxes		726		776
Property and equipment, at cost, less accumulated depreciation and amortization ($4,538 at March 31, 2016 and $4,323 at December 31, 2015)		7,961		7,915
Goodwill		7,122		6,970
Other intangible assets, at cost, less accumulated amortization ($701 at March 31, 2016 and $659 at December 31, 2015)		1,686		1,675
Total assets	$	23,766	$	23,682
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	172	$	127
Accounts payable		1,228		1,380
Accrued compensation and benefits		772		880
Professional and general liability reserves		161		177
Accrued interest payable		307		205
Liabilities held for sale		—		101
Accrued legal settlement costs		423		294
Other current liabilities		1,205		1,144
Total current liabilities		4,268		4,308
Long-term debt, net of current portion		14,350		14,383
Professional and general liability reserves		623		578
Defined benefit plan obligations		593		595
Other long-term liabilities		625		594
Total liabilities		20,459		20,458
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries		2,381		2,266
Equity:
Shareholders’ equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 147,692,493 shares issued at March 31, 2016 and 146,920,454 shares issued at December 31, 2015		7		7
Additional paid-in capital		4,804		4,815
Accumulated other comprehensive loss		(160)		(164)
Accumulated deficit		(1,609)		(1,550)
Common stock in treasury, at cost, 48,424,273 shares at March 31, 2016 and 48,425,298 shares at December 31, 2015		(2,417)		(2,417)
Total shareholders’ equity		625		691
Noncontrolling interests		301		267
Total equity		926		958
Total liabilities and equity	$	23,766	$	23,682

See accompanying Notes to Condensed Consolidated Financial Statements.

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Dollars in Millions, Except Per-Share Amounts

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues:
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787
Less: Provision for doubtful accounts		376		363
Net operating revenues		5,044		4,424
Equity in earnings of unconsolidated affiliates		24		4
Operating expenses:
Salaries, wages and benefits		2,402		2,125
Supplies		811		687
Other operating expenses, net		1,242		1,093
Electronic health record incentives		—		(6)
Depreciation and amortization		212		207
Impairment and restructuring charges, and acquisition-related costs		28		29
Litigation and investigation costs		173		3
Gains on sales, consolidation and deconsolidation of facilities		(147)		—
Operating income		347		290
Interest expense		(243)		(199)
Investment earnings		1		—
Net income from continuing operations, before income taxes		105		91
Income tax expense		(67)		(16)
Net income from continuing operations, before discontinued operations		38		75
Discontinued operations:
Loss from operations		(5)		(1)
Litigation and investigation costs		—		3
Income tax benefit (expense)		1		(1)
Net income (loss) from discontinued operations		(4)		1
Net income		34		76
Less: Net income attributable to noncontrolling interests		93		29
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$	(59)	$	47
Amounts available (attributable) to Tenet Healthcare Corporation common shareholders
Net income (loss) from continuing operations, net of tax	$	(55)	$	46
Net income (loss) from discontinued operations, net of tax		(4)		1
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$	(59)	$	47
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:
Basic
Continuing operations	$	(0.56)	$	0.47
Discontinued operations		(0.04)		0.01
	$	(0.60)	$	0.48
Diluted
Continuing operations	$	(0.56)	$	0.46
Discontinued operations		(0.04)		0.01
	$	(0.60)	$	0.47
Weighted average shares and dilutive securities outstanding (in thousands):
Basic		98,768		98,699
Diluted		98,768		100,872

See accompanying Notes to Condensed Consolidated Financial Statements.

2

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME

Dollars in Millions

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Net income	$	34	$	76
Other comprehensive income:
Amortization of net actuarial loss included in net periodic benefit costs		—		3
Unrealized gains on securities held as available-for-sale		3		1
Foreign currency translation adjustments		2		—
Other comprehensive income before income taxes		5		4
Income tax expense related to items of other comprehensive income		(1)		(1)
Total other comprehensive income, net of tax		4		3
Comprehensive net income		38		79
Less: Comprehensive income attributable to noncontrolling interests		93		29
Comprehensive net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$	(55)	$	50

See accompanying Notes to Condensed Consolidated Financial Statements.

3

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Dollars in Millions

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Net income	$	34	$	76
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		212		207
Provision for doubtful accounts		376		363
Deferred income tax expense		31		12
Stock-based compensation expense		16		15
Impairment and restructuring charges, and acquisition-related costs		28		29
Litigation and investigation costs		173		3
Gains on sales, consolidation and deconsolidation of facilities		(147)		—
Equity in earnings of unconsolidated affiliates, net of distributions received		12		(4)
Amortization of debt discount and debt issuance costs		10		7
Pre-tax loss (income) from discontinued operations		5		(2)
Other items, net		2		(4)
Changes in cash from operating assets and liabilities:
Accounts receivable		(453)		(484)
Inventories and other current assets		(18)		(74)
Income taxes		28		8
Accounts payable, accrued expenses and other current liabilities		(114)		(200)
Other long-term liabilities		24		28
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements		(69)		(33)
Net cash used in operating activities from discontinued operations, excluding income taxes		(3)		(4)
Net cash provided by (used in) operating activities		147		(57)
Cash flows from investing activities:
Purchases of property and equipment — continuing operations		(208)		(184)
Purchases of businesses or joint venture interests, net of cash acquired		(29)		(11)
Proceeds from sales of facilities and other assets		573		—
Proceeds from sales of marketable securities, long-term investments and other assets		12		6
Purchases of equity investments		(18)		—
Other long-term assets		(10)		2
Net cash provided by (used in) investing activities		320		(187)
Cash flows from financing activities:
Repayments of borrowings under credit facility		(995)		(690)
Proceeds from borrowings under credit facility		995		820
Repayments of other borrowings		(38)		(32)
Proceeds from other borrowings		1		401
Debt issuance costs		—		(4)
Distributions paid to noncontrolling interests		(44)		(11)
Contributions from noncontrolling interests		—		2
Purchase of noncontrolling interests		—		(254)
Proceeds from exercise of stock options		—		7
Other items, net		(14)		(3)
Net cash provided by (used in) financing activities		(95)		236
Net increase (decrease) in cash and cash equivalents		372		(8)
Cash and cash equivalents at beginning of period		356		193
Cash and cash equivalents at end of period	$	728	$	185
Supplemental disclosures:
Interest paid, net of capitalized interest	$	(132)	$	(117)
Income tax refunds (payments), net	$	(6)	$	1

See accompanying Notes to Condensed Consolidated Financial Statements.

4

TENET HEALTHCARE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At March 31, 2016, we operated 84 hospitals, 20 short-stay surgical hospitals, over 475outpatient centers, nine facilities in the United Kingdom and six health plans through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). The results of 142 of these facilities, in which we hold noncontrolling interests, are recorded using the equity method of accounting. Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2015 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  Certain prior-year amounts have been reclassified to conform to the current-year presentation.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three month period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the number of covered lives managed by our health plans and the plans’ ability to effectively manage medical costs; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of

5

uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Translation of Foreign Currencies

The accounts of European Surgical Partners, Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs.

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended
	March 31,
	2016		2015
General Hospitals:
Medicare	$	859	$	898
Medicaid		373		385
Managed care		2,626		2,405
Indemnity, self-pay and other		437		414
Acute care hospitals — other revenue		7		15
Other:
Other operations		1,118		670
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $728 million and $356 million at March 31, 2016 and December 31, 2015, respectively. At March 31, 2016 and December 31, 2015, our book overdrafts were approximately $256 million and $301 million, respectively, which were classified as accounts payable.

At March 31, 2016 and December 31, 2015, approximately $175 million and $171 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries and our health plans.

Also at March 31, 2016 and December 31, 2015, we had $110 million and $133 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $63 million and $95 million, respectively, were included in accounts payable.

6

During the three months ended March 31, 2016 and 2015, we entered into non-cancellable capital leases of approximately $31 million and $33 million, respectively, primarily for buildings and equipment.

Other Intangible Assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at March 31, 2016 and December 31, 2015:

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At March 31, 2016:
Capitalized software costs	$	1,495	$	(625)	$	870
Trade names		106		—		106
Contracts		669		(30)		639
Other		117		(46)		71
Total	$	2,387	$	(701)	$	1,686

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At December 31, 2015:
Capitalized software costs	$	1,456	$	(594)	$	862
Trade names		106		—		106
Contracts		653		(26)		627
Other		119		(39)		80
Total	$	2,334	$	(659)	$	1,675

Estimated future amortization of intangibles with finite useful lives at March 31, 2016 is as follows:

			Years Ending December 31,										Later
	Total		2016		2017		2018		2019		2020		Years
Amortization of intangible assets	$	1,207	$	141	$	174	$	146	$	122	$	89	$	535

Investments in Unconsolidated Affiliates

We control 213 of the facilities operated by our Ambulatory Care segment and, therefore, consolidate their results (211 are consolidated within our Ambulatory Care segment and two are consolidated within our Hospital Operations and other segment). We account for many of the facilities our Ambulatory Care segment operates (122 of 335 at March 31, 2016) and four of the hospitals our Hospital Operations and other segment operates under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. Summarized financial information for these equity method investees is included in the following table.

	Three Months Ended
	March 31, 2016
Net operating revenues	$	578
Net income	$	105
Net income attributable to the investees	$	69

7

NOTE 2. ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The principal components of accounts receivable are shown in the table below:

	March 31,		December 31,
	2016		2015
Continuing operations:
Patient accounts receivable	$	3,606	$	3,486
Allowance for doubtful accounts		(901)		(887)
Estimated future recoveries from accounts assigned to our Conifer subsidiary		146		144
Net cost reports and settlements payable and valuation allowances		(47)		(42)
		2,804		2,701
Discontinued operations		3		3
Accounts receivable, net	$	2,807	$	2,704

At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts was 25.0% and 25.4%, respectively, of our patient accounts receivable. Accounts that are pursued for collection through Conifer’s regional business offices are maintained on our hospitals’ books and reflected in patient accounts receivable with an allowance for doubtful accounts established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimate this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors. At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts for self-pay was 81.2% and 80.6%, respectively, of our self-pay patient accounts receivable, including co-pays and deductibles owed by patients with insurance. At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts for managed care was 8.4% and 7.5%, respectively, of our managed care patient accounts receivable.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. The table below shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our self-pay patients and charity care patients, and revenues attributable to Medicaid DSH and other supplemental revenues we recognized in three months ended March 31, 2016 and 2015.

	Three Months Ended
	March 31,
	2016		2015
Estimated costs for:
Self-pay patients	$	165	$	164
Charity care patients	$	44	$	36
Medicaid DSH and other supplemental revenues	$	227	$	247

At March 31, 2016 and December 31, 2015, we had approximately $450 million and $387 million, respectively, of receivables recorded in other current assets and approximately $174 million and $139 million, respectively, of payables recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program.

NOTE 3. ASSETS AND LIABILITIES HELD FOR SALE

Our hospitals, physician practices and related assets in Georgia met the criteria to be classified as assets held for sale in the three months ended June 30, 2015. In accordance with the guidance in the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 360, “Property, Plant and Equipment,” we classified $549 million of

8

our assets in Georgia as “assets held for sale” in current assets and $101 million of our liabilities in Georgia as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at December 31, 2015. We completed the sale of our Georgia assets on March 31, 2016 at a transaction price of approximately $575 million and recognized a gain on sale of approximately $113 million. Because we did not sell the related accounts receivable related to the pre-closing period, net receivables of approximately $141 million are included in accounts receivable, less allowance for doubtful accounts in the accompanying Condensed Consolidated Balance Sheet at March 31, 2016.

NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

During the three months ended March 31, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $28 million primarily related to our Hospital Operations and other segment, consisting of approximately $2 million to write-down other intangible assets, $10 million of employee severance costs, $1 million of restructuring costs, $1 million of contract and lease termination fees, and $14 million in acquisition-related costs, which include $5 million of transaction costs and $9 million of acquisition integration charges.

During the three months ended March 31, 2015, we recorded impairment and restructuring charges and acquisition-related costs of $29 million, consisting of $6 million of employee severance costs, $3 million of restructuring costs, and $20 million in acquisition-related costs, which include $7 million of transaction costs and $13 million of acquisition integration charges.

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve the facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

At March 31, 2016, our continuing operations consisted of three reportable segments, Hospital Operations and other, Ambulatory Care and Conifer.Within our Hospital Operations and other segment, our regions and markets are reporting units used to perform our goodwill impairment analysis and are one level below our reportable business segment level. Our Ambulatory Care segment consists of the operations of our USPI joint venture and our Aspen facilities.

Our Hospital Operations and other segment was structured as follows at March 31, 2016:

· Our Florida region included all of our hospitals and other operations in Florida;

· Our Northeast region included all of our hospitals and other operations in Illinois, Massachusetts and Pennsylvania;

· Our Southern region included all of our hospitals and other operations in Alabama, Georgia, South Carolina and Tennessee;

· Our Texas region included all of our hospitals and other operations in Missouri, New Mexico and Texas;

· Our Western region included all of our hospitals and other operations in Arizona and California; and

· Our Detroit market included all of our hospitals and other operations in the Detroit, Michigan area.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

9

NOTE 5. LONG-TERM DEBT AND LEASE OBLIGATIONS

The table below shows our long-term debt at March 31, 2016 and December 31, 2015:

	March 31,		December 31,
	2016		2015
Senior notes:
5%, due 2019	$	1,100	$	1,100
51/2%, due 2019		500		500
63/4%, due 2020		300		300
8%, due 2020		750		750
81/8%, due 2022		2,800		2,800
63/4%, due 2023		1,900		1,900
67/8%, due 2031		430		430
Senior secured notes:
61/4%, due 2018		1,041		1,041
43/4%, due 2020		500		500
6%, due 2020		1,800		1,800
Floating % due 2020		900		900
41/2%, due 2021		850		850
43/8%, due 2021		1,050		1,050
Capital leases and mortgage notes		853		852
Unamortized issue costs, note discounts and premium		(252)		(263)
Total long-term debt		14,522		14,510
Less current portion		172		127
Long-term debt, net of current portion	$	14,350	$	14,383

Credit Agreement

On December 4, 2015, we entered into an amendment to our existing senior secured revolving credit facility (as amended, “Credit Agreement”) in order to, among other things, extend the scheduled maturity date of the facility, reduce the rates of certain interest and fees payable under the facility, and remove certain restrictions with respect to the borrowing base eligibility of certain accounts receivable. The Credit Agreement provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. The Credit Agreement, which has a scheduled maturity date of December 4, 2020, is collateralized by patient accounts receivable of substantially all of our domestic wholly owned hospitals. In addition, borrowings under the Credit Agreement are guaranteed by substantially all of our wholly owned domestic hospital subsidiaries. Outstanding revolving loans accrue interest at a base rate plus a margin ranging from 0.25% to 0.75% per annum or the London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.25% to 1.75% per annum, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible accounts receivable, including self-pay accounts. At March 31, 2016, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $4 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $996 million was available for borrowing under the Credit Agreement at March 31, 2016.

Letter of Credit Facility

On March 7, 2014, we entered into a letter of credit facility agreement (“LC Facility”) that provides for the issuance of standby and documentary letters of credit (including certain letters of credit issued under our prior credit agreement, which we transferred to the LC Facility (the “Preexisting Letters of Credit”)), from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The LC Facility has a scheduled maturity date of March 7, 2017, and obligations thereunder are guaranteed by and secured by a first priority pledge of the capital stock and other ownership interests of certain of our domestic hospital subsidiaries on an equal ranking basis with our existing senior secured notes.

10

Drawings under any letter of credit issued under the LC Facility (including the Preexisting Letters of Credit) that we have not reimbursed within three business days after notice thereof will accrue interest at a base rate plus a margin equal to 0.875% per annum. An unused commitment fee is payable at an initial rate of 0.50% per annum with a step down to 0.375% per annum based on the secured debt to EBITDA ratio of 3.00 to 1.00. A per annum fee on the aggregate outstanding amount of issued but undrawn letters of credit (including the Preexisting Letters of Credit) will accrue at a rate of 1.875% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At March 31, 2016, we had approximately $139 million of standby letters of credit outstanding under the LC Facility.

NOTE 6. GUARANTEES

At March 31, 2016, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $89 million. We had a total liability of $75 million recorded for these guarantees included in other current liabilities at March 31, 2016.

At March 31, 2016, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $35 million. Of the total, $17 million relates to the obligations of consolidated subsidiaries, which obligations are recorded in the accompanying Condensed Consolidated Balance Sheet at March 31, 2016.

NOTE 7. EMPLOYEE BENEFIT PLANS

At March 31, 2016, approximately 1.7 million shares of common stock were available under our 2008 Stock Incentive Plan for future stock option grants and other incentive awards, including restricted stock units. Options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unit is a contractual right to receive one share of our common stock or the equivalent value in cash in the future. Options and time-based restricted stock units typically vest one-third on each of the first three anniversary dates of the grant; however, certain special retention awards may have longer vesting periods. In addition, we grant performance-based restricted stock units (and, in prior years, have granted performance-based options) that vest subject to the achievement of specified performance goals within a specified timeframe.

Our Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 include $14 million and $18 million, respectively, of pretax compensation costs related to our stock-based compensation arrangements recorded in salaries, wages and benefits.

Stock Options

The following table summarizes stock option activity during the three months ended March 31, 2016:

		Weighted Average
		Exercise Price		Aggregate		Weighted Average
	Options	Per Share		Intrinsic Value		Remaining Life
					(In Millions)
Outstanding at December 31, 2015	1,606,842	$	22.87
Granted	—		—
Exercised	(3,950)		4.56
Forfeited/Expired	(29,392)		4.56
Outstanding at March 31, 2016	1,573,500		22.75	$	13	2.9	years
Vested and expected to vest at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years
Exercisable at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years

11

There were 3,950 stock options exercised during the three months ended March 31, 2016 with an aggregate intrinsic value of less than $1 million, and 77,658 stock options exercised during the same period in 2015 with a less than $1 million aggregate intrinsic value.

At March 31, 2016, there were no unrecognized compensation costs related to stock options. Also, there were no stock options granted in the three months ended March 31, 2016 or 2015.

The following table summarizes information about our outstanding stock options at March 31, 2016:

	Options Outstanding					Options Exercisable
		Weighted Average
	Number of	Remaining		Weighted Average		Number of	Weighted Average
Range of Exercise Prices	Options	Contractual Life		Exercise Price		Options	Exercise Price
$0.00 to $4.569	202,152	2.9	years	$	4.56	202,152	$	4.56
$4.57 to $25.089	910,897	3.6	years		20.99	910,897		20.99
$25.09 to $32.569	182,000	0.9	years		26.40	182,000		26.40
$32.57 to $42.529	278,451	1.8	years		39.31	278,451		39.31
	1,573,500	2.9	years	$	22.75	1,573,500	$	22.75

Restricted Stock Units

The following table summarizes restricted stock unit activity during the three months ended March 31, 2016:

	Restricted Stock	Weighted Average Grant
	Units	Date Fair Value Per Unit
Unvested at December 31, 2015	3,627,232	$	44.69
Granted	1,231,727		31.08
Vested	(1,223,015)		43.68
Forfeited	(23,639)		45.05
Unvested at March 31, 2016	3,612,305	$	40.38

In the three months ended March 31, 2016, we granted 474,052 restricted stock units subject to time-vesting, of which 458,379 will vest and be settled ratably over a three-year period from the grant date, and 15,673 will vest and be settled on the third anniversary of the grant date. In January 2016, following the appointment of two new members of our Board of Directors, we also made initial grants totaling 5,084restricted stock units to these directors, as well as prorated annual grants totaling 5,614 restricted stock units. Both the initial grants and the annual grants vested immediately, however the initial grants will not settle until the directors’ separation from the Board, while the annual grants settle on the third anniversary of the grant date. In addition, we granted 455,437 performance-based restricted stock units to certain of our senior officers; the vesting of these restricted stock units is contingent on our achievement of specified three-year performance goals for the years 2016 to 2018. Provided the goals are achieved, the performance-based restricted stock units will vest and settle on the third anniversary of the grant date. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 455,437 units granted, depending on our level of achievement with respect to the performance goals. Moreover, in the three months ended March 31, 2016, we granted 291,540 restricted stock units as a result of our level of achievement with respect to prior-year target performance goals.

At March 31, 2016, there were $117 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 2.3 years.

NOTE 8. EQUITY

Changes in Shareholders’ Equity

The following table shows the changes in consolidated equity during the three months ended March 31, 2016 and 2015 (dollars in millions, share amounts in thousands):

12

	Tenet Healthcare Corporation Shareholders’ Equity
						Accumulated
	Common Stock			Additional		Other
	Shares	Issued Par		Paid-in		Comprehensive		Accumulated		Treasury		Noncontrolling
	Outstanding	Amount		Capital		Loss		Deficit		Stock		Interests		Total Equity
Balances at December 31, 2015	98,495	$	7	$	4,815	$	(164)	$	(1,550)	$	(2,417)	$	267	$	958
Net income  (loss)	—		—		—		—		(59)		—		13		(46)
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		10		10
Other comprehensive income	—		—		—		4		—		—		—		4
Purchases (sales) of businesses and noncontrolling interests	—		—		(7)		—		—		—		21		14
Stock-based compensation expense, tax benefit and issuance of common stock	773		—		(4)		—		—		—		—		(4)
Balances at March 31, 2016	99,268	$	7	$	4,804	$	(160)	$	(1,609)	$	(2,417)	$	301	$	926
Balances at December 31, 2014	98,382	$	7	$	4,614	$	(182)	$	(1,410)	$	(2,378)	$	134	$	785
Net income	—		—		—		—		47		—		8		55
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		1		1
Other comprehensive income	—		—		—		3		—		—		—		3
Purchases (sales) of businesses and noncontrolling interests	—		—		129		—		—		—		—		129
Stock-based compensation expense and issuance of common stock	782		—		8		—		—		1		—		9
Balance at March 31, 2015	99,164	$	7	$	4,751	$	(179)	$	(1,363)	$	(2,377)	$	133	$	972

NOTE 9. PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

Property Insurance

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis.

Professional and General Liability Reserves

At March 31, 2016 and December 31, 2015, the aggregate current and long-term professional and general liability reserves in our accompanying Condensed Consolidated Balance Sheets were approximately $784 million and $755 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 1.54% at March 31, 2016 and 2.09% at December 31, 2015.

If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

Included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations is malpractice expense of $93 million and $89 million for the three months ended March 31, 2016 and 2015, respectively.

13

NOTE 10. CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. As a result, we commonly become involved in disputes, litigation and regulatory matters incidental to our operations, including governmental investigations, personal injury lawsuits, employment claims and other matters arising out of the normal conduct of our business.

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information.

Governmental Reviews and Lawsuits

Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. The following matters are pending.

· Clinica de la Mama Qui Tam Action and Criminal Investigation—As previously disclosed, we and four of our hospital subsidiaries are defendants in civil qui tam litigation (United States of America, ex rel. Ralph D. Williams v. Health Management Associates, Inc., et al.) that alleges that the contractual arrangements entered into by the hospital subsidiaries with Hispanic Medical Management, Inc. (“HMM”) violated the federal and state anti-kickback statutes and false claims acts. HMM owned and operated clinics that provided, among other things, prenatal care predominantly to uninsured patients. Beginning in 2000, the hospital subsidiaries contracted with HMM for translation, marketing, management and Medicaid eligibility determination services. Subsequently, the Georgia Attorney General’s Office and the U.S. Attorney’s Office intervened in the qui tam action. Effective March 31, 2016, we sold the operating assets of three of the four hospital subsidiaries; however, we retained any potential liabilities arising from the litigation or the U.S. Department of Justice (“DOJ”) investigation discussed below.

If the plaintiff in the pending civil litigation were to prevail, the potential sanctions could include up to three times the reimbursement of relevant government program payments received by the four hospital subsidiaries for uninsured HMM patients treated at the hospitals, the assessment of civil penalties and potential exclusion from participation in federal healthcare programs.

Also as previously disclosed, the DOJ has been conducting a criminal investigation of us, certain of our subsidiaries and former employees with respect to the contractual arrangements between HMM and the four hospitals. We are cooperating in the investigation and have responded, and continue to respond, to document and other requests pursuant to subpoenas issued to us and the four subsidiaries.

In January 2016, we commenced discussions with the DOJ and the State of Georgia regarding potential resolution of the qui tam action and criminal investigation. In the three months ended March 31, 2016, we increased the aggregate accrual for these matters from $238 million to $407 million to reflect the most recent  offer we made on April 25, 2016 to resolve the criminal investigation and civil litigation. The offer was not accepted, but the parties continue to engage in discussions to resolve these matters. There can be no assurance that ongoing discussions will lead to a resolution. The terms of a final resolution of these matters may require us to pay significant fines and penalties and give rise to other costs or adverse consequences that materially exceed the accrual we have established. Based on the ongoing uncertainties and potentially wide range of

14

outcomes associated with any potential resolution, we cannot estimate the amount of potential loss or range of reasonably possible loss in excess of the amount accrued that we may face.

In addition to the payment of a monetary penalty, the final terms of any resolution of these matters could include: (i) the execution by the Company of a Corporate Integrity Agreement or a non-prosecution agreement, which may provide for the appointment of a corporate monitor and ongoing compliance audits; (ii) a deferred prosecution agreement by an intermediate subsidiary of the Company; and (iii) a commitment that one or more of the hospital subsidiaries subject to the investigation and proceedings enter into a guilty plea. The non-monetary terms of any resolution could expose us to increased operating costs, reputational harm, administrative burdens, and diminished profits and revenues.

If our efforts to negotiate a settlement ultimately are unsuccessful, and we or our subsidiaries are determined to have violated the federal anti-kickback statute, the sanctions could include fines, which could be significant, and mandatory exclusion from participation in federal healthcare programs.

To the extent that either the civil or criminal matter discussed above is determined adversely to our interests, such determination could have a material adverse effect on our business, financial condition, results of operations or cash flows. 

Antitrust Class Action Lawsuit Filed by Registered Nurses in San Antonio

In Maderazo, et al. v. VHS San Antonio Partners, L.P. d/b/a Baptist Health Systems, et al., filed in June 2006 in the U.S. District Court for the Western District of Texas, a purported class of registered nurses employed by three unaffiliated San Antonio-area hospital systems allege those hospital systems, including Baptist Health System, and other unidentified San Antonio regional hospitals violated Section §1 of the federal Sherman Act by conspiring to depress nurses’ compensation and exchanging compensation-related information among themselves in a manner that reduced competition and suppressed the wages paid to such nurses. The suit seeks unspecified damages (subject to trebling under federal law), interest, costs and attorneys’ fees. The case had been stayed since 2008; however, in July 2015, the court lifted the stay and re-opened discovery. Because these proceedings are at an early stage, it is impossible at this time to predict their outcome with any certainty; however, we believe that the ultimate resolution of this matter will not have a material effect on our business, financial condition or results of operations. We will continue to seek to defeat class certification and vigorously defend ourselves against the plaintiffs’ allegations.

Ordinary Course Matters

We are also subject to other claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.

15

The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the three months ended March 31, 2016 and 2015:

	Balances at		Litigation and				Balances at
	Beginning		Investigation		Cash		End of
	of Period		Costs		Payments		Period
Three Months Ended March 31, 2016
Continuing operations	$	299	$	173	$	(45)	$	427
Discontinued operations		—		—		—		—
	$	299	$	173	$	(45)	$	427
Three Months Ended March 31, 2015
Continuing operations	$	73	$	3	$	(15)	$	61
Discontinued operations		10		(3)		—		7
	$	83	$	—	$	(15)	$	68

For the three months ended March 31, 2016 and 2015, we recorded costs of $173 million and $3 million, respectively, in continuing operations in connection with significant legal proceedings and governmental reviews. During the three months ended March 31, 2015, we reduced a previously established reserve for a legal matter in discontinued operations by approximately $3 million based on updated claims information.

NOTE 11. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016		2015
Balances at beginning of period	$	2,266	$	401
Net income		80		21
Distributions paid to noncontrolling interests		(34)		(1)
Contributions from noncontrolling interests		6		1
Purchases and sales of businesses and noncontrolling interests, net		63		(214)
Balances at end of period	$	2,381	$	208

NOTE 12. INCOME TAXES

During the three months ended March 31, 2016, we recorded income tax expense of $67 million in continuing operations on pre-tax earnings of $105 million. The recorded income tax differs from taxes calculated at the statutory rate primarily due to state income tax expense of approximately $13 million, tax benefits of $21 million related to net income attributable to noncontrolling partnership interests, which is excluded from the computation of the provision for income taxes, tax expense of $29 million related to nondeductible goodwill, tax benefits of $17 million related to nontaxable gains and related changes in deferred taxes, and tax expense of $26 million related to nondeductible litigation.

During the three months ended March 31, 2016, we decreased our estimated liabilities for uncertain tax positions by $3 million, net of related deferred tax assets. The total amount of unrecognized tax benefits at March 31, 2016 was $37 million, of which $34 million, if recognized, would impact our effective tax rate and income tax expense (benefit) from continuing operations.

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accrued interest and penalties on unrecognized tax benefits at March 31, 2016 were $5 million, all of which related to continuing operations.

16

At March 31, 2016, approximately $6 million of unrecognized federal and state tax benefits, as well as reserves for interest and penalties, may decrease in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

NOTE 13. EARNINGS (LOSS) PER COMMON SHARE

The table below is a reconciliation of the numerators and denominators of our basic and diluted earnings (loss) per common share calculations for our continuing operations for three months ended March 31, 2016 and 2015. Net income available (loss attributable) to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

	Net Income Available
	(Loss Attributable)
	to Common		Weighted
	Shareholders		Average Shares	Per-Share
	(Numerator)		(Denominator)	Amount
Three Months Ended March 31, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(55)	98,768	$	(0.56)
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	—		—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(55)	98,768	$	(0.56)
Three Months Ended March 31, 2015
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	46	98,699	$	0.47
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	2,173		(0.01)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	46	100,872	$	0.46

All potentially dilutive securities were excluded from the calculation of diluted loss per share for the three months ended March 31, 2016 because we did not report income from continuing operations available to common shareholders in that period. In circumstances where we do not have income from continuing operations available to common shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive, that is, a loss from continuing operations attributable to common shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the three months ended March 31, 2016, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase of 1,567 shares.

NOTE 14. FAIR VALUE MEASUREMENTS

Our financial assets and liabilities recorded at fair value on a recurring basis primarily relate to investments in available-for-sale securities held by our captive insurance subsidiaries. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are

unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

17

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	March 31, 2016		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	60	$	25	$	35	$	—
	$	60	$	25	$	35	$	—

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	December 31, 2015		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	59	$	24	$	35	$	—
	$	59	$	24	$	35	$	—

The fair value of our long-term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At March 31, 2016 and December 31, 2015, the estimated fair value of our long-term debt was approximately 99.1% and 96.2%, respectively, of the carrying value of the debt.

NOTE 15. ACQUISITIONS

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the three months ended March 31, 2016 are as follows:

Current assets	$	30
Property and equipment		24
Other intangible assets		5
Goodwill		114
Other long-term assets		6
Current liabilities		(9)
Other long-term liabilities		(13)
Redeemable noncontrolling interests in equity of consolidated subsidiaries		(62)
Noncontrolling interests		(37)
Cash paid, net of cash acquired		(29)
Gains on consolidations	$	29

The goodwill generated from these transactions, the majority of which will not be deductible for income tax purposes, was recorded in our Ambulatory Care segment and can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Approximately $5 million in transaction costs related to prospective and closed acquisitions were expensed during the three months ended March 31, 2016, and are included in impairment and restructuring charges, and acquisition-related costs in the accompanying Condensed Consolidated Statement of Operations.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocation over those fair values is recorded as goodwill. We are in process of finalizing the purchase price allocations, including valuations of the acquired property and equipment, other intangible assets, investments in affiliates and noncontrolling interests for our 2016 and 2015 acquisitions; therefore, those purchase price allocations are subject to adjustment once the valuations are completed.

During the three months ended March 31, 2016,  we recognized gains totaling $29 million, associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests.

18

Pro Forma Information – Unaudited

The following table provides 2016 actual results compared to 2015 pro forma information for Tenet as if the USPI joint venture and Aspen acquisition had occurred at the beginning of the year ended December 31, 2015.

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	5,044	$	4,629
Equity in earnings of unconsolidated affiliates	$	24	$	25
Net income available (loss attributable) to common shareholders	$	(59)	$	28
Earnings (loss) per share available (attributable) to common shareholders	$	(0.60)	$	0.28

NOTE 16. SEGMENT INFORMATION

Our business consists of our Hospital Operations and other segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our core business is Hospital Operations and other, which is focused on operating acute care hospitals, ancillary outpatient facilities, freestanding emergency departments, physician practices and health plans. We also own various related healthcare businesses. At March 31, 2016, our subsidiaries operated 84 hospitals, with a total of 21,529 licensed beds, primarily serving urban and suburban communities in 13 states, and six health plans, as well as hospital-based outpatient centers, freestanding emergency departments and freestanding urgent care centers.

Our Ambulatory Care segment is comprised of the operations of our USPI joint venture and our nine Aspen facilities in the United Kingdom. At March 31, 2016, our USPI joint venture had interests in 250 ambulatory surgery centers, 35 urgent care centers, 21 imaging centers and 20 short-stay surgical hospitals in 28 states.

Our Conifer segment provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans. At March 31, 2016, Conifer provided services to more than 800 Tenet and non-Tenet hospitals and other clients nationwide. Our Conifer subsidiary and our Hospital Operations and other segment entered into formal agreements documenting terms and conditions of various services provided by Conifer to Tenet hospitals, as well as certain administrative services provided by our Hospital Operations and other segment to Conifer. The services provided by both parties under these agreements are charged to the other party based on estimated third-party pricing terms.

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:

	March 31,		December 31,
	2016		2015
Assets:
Hospital Operations and other	$	17,131	$	17,353
Ambulatory Care		5,467		5,159
Conifer		1,168		1,170
Total	$	23,766	$	23,682

19

	Three Months Ended
	March 31,
	2016		2015
Capital expenditures:
Hospital Operations and other	$	191	$	176
Ambulatory Care		12		4
Conifer		5		4
Total	$	208	$	184
Net operating revenues:
Hospital Operations and other	$	4,397	$	4,151
Ambulatory Care		429		91
Conifer
Tenet		167		160
Other customers		218		182
Total Conifer revenues		385		342
Intercompany eliminations		(167)		(160)
Total	$	5,044	$	4,424
Adjusted EBITDA:
Hospital Operations and other	$	414	$	418
Ambulatory Care		136		29
Conifer		63		82
Total	$	613	$	529
Depreciation and amortization:
Hospital Operations and other	$	174	$	192
Ambulatory Care		25		4
Conifer		13		11
Total	$	212	$	207
Adjusted EBITDA	$	613	$	529
Depreciation and amortization		(212)		(207)
Impairment and restructuring charges, and acquisition-related costs		(28)		(29)
Litigation and investigation costs		(173)		(3)
Interest expense		(243)		(199)
Gains on sales, consolidation and deconsolidation of facilities		147		—
Investment earnings		1		—
Net income from continuing operations before income taxes	$	105	$	91

NOTE 17. RECENT ACCOUNTING STANDARDS

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which affects any entity that enters into a lease (as that term is defined in ASU 2016-02), with some specified scope exceptions. The main difference between the guidance in ASU 2016-02 and previous GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2019.

In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which affects all entities that issue share-based payment awards to their employees. The guidance in ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas of simplification apply

20

only to nonpublic entities. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2017.

NOTE 18. SUBSEQUENT EVENTS

As previously disclosed, as part of the formation of our USPI joint venture in 2015, we entered into a put/call agreement (the “Put/Call Agreement”) with respect to the equity interests in the joint venture held by our joint venture partners. Each year starting in 2016, our joint venture partners must put to us at least 12.5%, and may put up to 25%, of the equity held by them in the joint venture immediately after the closing. In January 2016, Welsh, Carson, Anderson & Stowe, on behalf of our joint venture partners, delivered a put notice for the minimum number of shares they are required to put to us in 2016 according to the Put/Call Agreement. In April 2016, we paid approximately $127 million to purchase these shares, which increased our ownership interest in the USPI joint venture to approximately 56.3%.

21

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our core business is our Hospital Operations and other segment, which is focused on operating acute care hospitals, ancillary outpatient facilities, freestanding emergency departments, physician practices and health plans. Our Ambulatory Care segment is comprised of the operations of our USPI Holding Company, Inc. (“USPI joint venture”), in which we acquired a majority interest on June 16, 2015, and European Surgical Partners Limited (“Aspen”) facilities, which we also acquired on June 16, 2015. At March 31, 2016, our USPI joint venture had interests in 250 ambulatory surgery centers, 35 urgent care centers, 21 imaging centers and 20 short-stay surgical hospitals in 28 states, and Aspen operated nine private hospitals and clinics in the United Kingdom. Our Conifer segment provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

· Management Overview

· Forward-Looking Statements

· Sources of Revenue

· Results of Operations

· Liquidity and Capital Resources

· Off-Balance Sheet Arrangements

· Critical Accounting Estimates

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per share, per admission, per adjusted admission, per patient day, per adjusted patient day, per visit and per case amounts). Continuing operations information includes the results of (i) our same 72 hospitals and six health plans operated throughout the three months ended March 31, 2016 and 2015,

(ii) our USPI joint venture, in which we acquired a majority interest on June 16, 2015, (iii) Aspen, which we also acquired on June 16, 2015, (iv) Hi-Desert Medical Center, which we began operating on July 15, 2015, (v) our Carondelet Heath Network joint venture, in which we acquired a majority interest on August 31, 2015, (vi) Saint Louis University Hospital, which we divested on August 31, 2015, (vii) our joint venture with Baptist Health System, Inc., which we formed on October 2, 2015, (viii) DMC Surgery Hospital, which we closed in October 2015, (ix) Central Carolina Hospital and Frye Regional Medical Center, which we divested effective January 1, 2016, and (x) Centennial Medical Center, Doctors Hospital at White Rock Lake, Lake Pointe Medical Center, and Texas Regional Medical Center at Sunnyvale (collectively, “our North Texas hospitals”), in which we divested a controlling interest effective January 1, 2016, but continue to operate, in each case only for the period from acquisition, or commencement of operations of the facility, as the case may be, to March 31, 2016 and 2015 or to the date of divestiture, as applicable. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes. Certain previously reported information, primarily related to our freestanding ambulatory surgery and imaging center assets that were contributed to the USPI joint venture, has been reclassified to conform to the current-year presentation.

22

These outpatient facilities were formerly part of our Hospital Operations and other segment, but are now reported as part of our new Ambulatory Care segment.  

MANAGEMENT OVERVIEW

RECENT DEVELOPMENTS

USPI Put Notice—In January 2016, Welsh, Carson, Anderson & Stowe, on behalf of our USPI joint venture partners, delivered a put notice for the minimum number of shares they are required to put to us in 2016 according to a previously disclosed put/call agreement. In April 2016, we paid approximately $127 million to purchase shares subject to the put notice, which increased our ownership interest in the USPI joint venture to approximately 56.3%.

Sale of Georgia Hospitals—On March 31, 2016, we completed the sale of our Atlanta-area hospitals – Atlanta Medical Center and its South Campus, North Fulton Hospital, Spalding Regional Hospital and Sylvan Grove Hospital – as well as 26 physician clinics.  As a result of this transaction, we recorded a pre-tax gain on sale of approximately $113 million in the three months ended March 31, 2016.

STRATEGIES AND TRENDS

We are committed to providing the communities we serve with high quality, cost-effective healthcare while growing our business, increasing our profitability and creating long-term value for our shareholders. We believe that our success in increasing our profitability depends in part on our success in executing the strategies and managing the trends discussed below.

Core Business Strategy—We are focused on providing high quality care to patients through our hospitals and outpatient centers, and offering an array of business process solutions primarily to healthcare providers through Conifer. With respect to our hospitals, ambulatory care centers and other outpatient businesses, we seek to offer superior quality and patient services to meet community needs, to make capital and other investments in our facilities and technology, to recruit and retain physicians, and to negotiate competitive contracts with managed care and other private payers. With respect to business process services, we provide comprehensive operational management for revenue cycle functions, including patient access, health information management, revenue integrity and patient financial services. We also offer communication and engagement solutions to optimize the relationship between providers and patients. In addition, Conifer operates a management services business that supports value-based performance through clinical integration, financial risk management and population health management.

Commitment to Quality—We are continuing to make significant investments in equipment, technology, education and operational strategies designed to improve clinical quality at all of our facilities. In addition, we continually collaborate with physicians to implement the most current evidence-based medicine techniques to improve the way we provide care, while using labor management tools and supply chain initiatives to reduce variable costs. We believe the use of these practices will promote the most effective and efficient utilization of resources and result in shorter lengths of stay and reductions in readmissions for hospitalized patients.

Development Strategies—We remain focused on opportunities to increase our hospital and outpatient revenues, and to expand our Conifer services business, through organic growth, corporate development activities and strategic partnerships.

From time to time, we build new facilities, make acquisitions of healthcare assets and companies, and enter into joint venture arrangements or affiliations with healthcare businesses in markets where we believe our operating strategies can improve performance and create shareholder value. Effective January 1, 2016, we formed two joint ventures with Baylor Scott & White Health (“BSW”) involving the ownership and operation of our North Texas hospitals – which were

23

operated by certain of our subsidiaries – and Baylor Medical Center at Garland – which was operated by BSW. The joint ventures will focus on delivering integrated, value-based care primarily to select communities in Rockwall, Collin and Dallas counties. BSW holds a majority ownership interest in the joint ventures.

Historically, our outpatient services have generated significantly higher margins for us than inpatient services. During the three months ended March 31, 2016, we derived approximately 40% of our net patient revenues from outpatient services. By expanding our outpatient business, we expect to increase our profitability over time. The surgical facilities in our USPI joint venture specialize in non‑emergency surgical cases. Due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable in a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to steadily increase. In addition, we have continued growing our imaging and urgent care businesses through our USPI joint venture’s acquisitions, including the December 31, 2015 acquisition of CareSpot Express Healthcare, which added 35 urgent care centers in Florida and Tennessee to our USPI joint venture’s portfolio of outpatient centers. These acquisitions reflect our broader strategies to (1) offer more services to patients, (2) broaden the capabilities we offer to health system and physician partners to include other outpatient settings beyond the core ambulatory care business, and (3) expand into faster-growing, less capital intensive, higher-margin businesses. Furthermore, we continually evaluate joint venture opportunities with other healthcare providers in our markets to maximize effectiveness, reduce costs and build clinically integrated networks that provide quality services across the care continuum.

We intend to continue to market and expand Conifer’s revenue cycle management, patient communications and engagement services, and management services businesses. Conifer provides services to more than 800 Tenet and non-Tenet hospital and other clients nationwide. Historically, this business has generated high margins and improved our overall results of operations. Conifer’s service offerings have also expanded to support value-based performance through clinical integration, financial risk management and population health management, which are integral parts of the healthcare industry’s movement toward accountable care organizations (“ACOs”) and similar risk-based or capitated contract models. In addition to hospitals and independent physician associations, clients for these services include health plans, self-insured employers, government agencies and other entities. We also remain focused on developing, acquiring or entering into joint venture arrangements to establish new capabilities at Conifer.

General Economic Conditions—We believe that slow wage growth in some of the markets our hospitals serve and other adverse economic conditions have had a negative impact on our bad debt expense levels and payer mix. However, as the economy continues to recover, we expect to experience improvements in these metrics relative to recent levels. We believe our volumes were positively impacted in the three months ended March 31, 2016 by incremental market share we generated through improved physician alignment and service line expansion, insurance coverage for a greater number of individuals, and a strengthening economy.

Improving Operating Leverage—We believe targeted capital spending on critical growth opportunities for our hospitals, emphasis on higher-demand clinical service lines (including outpatient lines), focus on expanding our outpatient business, implementation of new payer contracting strategies, and improved quality metrics at our hospitals will improve our patient volumes. We believe our patient volumes have been constrained by the slow pace of the current economic recovery, increased competition, utilization pressure by managed care organizations, the effects of higher patient co-pays and deductibles, and demographic trends. In addition, in several markets, we have formed clinically integrated organizations, which are collaborations with independent physicians and hospitals to develop ongoing clinical initiatives designed to control costs and improve the quality of care delivered to patients. Arrangements like these provide a foundation for negotiating with plans under an ACO structure or other risk-sharing model.

Impact of the Affordable Care Act—We anticipate that we will continue to benefit over time from the provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”) that have extended insurance coverage through Medicaid or private insurance to a broader segment of the U.S. population. Although we are unable to predict the ultimate net effect of the Affordable Care Act on our future results of operations, and while there have been and will continue to be some reductions in reimbursement rates by governmental payers, we began to receive reimbursement for caring for previously uninsured and underinsured patients in 2014. Through collaborative efforts with local community organizations, we launched a campaign under the banner “Path to Health” to assist our hospitals in educating and enrolling uninsured patients in insurance plans. At

24

March 31, 2016, we operated hospitals in six of the states (Arizona, California, Illinois, Massachusetts, Michigan and Pennsylvania) that have expanded their Medicaid programs.

Our ability to execute on these strategies and manage these trends is subject to a number of risks and uncertainties that may cause actual results to be materially different from expectations. In addition, it is important that we make steady and measurable progress in successfully integrating acquired businesses and new joint ventures into our business processes, as appropriate. For information about risks and uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

RESULTS OF OPERATIONS—OVERVIEW

The following tables show operating statistics for our continuing operations, which includes the results of (i) our same 72 hospitals and six health plans operated throughout the three months ended March 31, 2016 and 2015,  (ii) our USPI joint venture, in which we acquired a majority interest on June 16, 2015, (iii) Aspen, which we also acquired on June 16, 2015, (iv) Hi-Desert Medical Center, which we began operating on July 15, 2015, (v) our Carondelet Heath Network joint venture, in which we acquired a majority interest on August 31, 2015, (vi) Saint Louis University Hospital, which we divested on August 31, 2015, (vii) our joint venture with Baptist Health System, Inc., which we formed on October 2, 2015, (viii) DMC Surgery Hospital, which we closed in October 2015, (ix) Central Carolina Hospital and Frye Regional Medical Center, which we divested effective January 1, 2016, and (x) our North Texas hospitals, in which we divested a controlling interest effective January 1, 2016, but continue to operate, in each case only for the period from acquisition, or commencement of operations of the facility, as the case may be, to March 31, 2016 and 2015 or to the date of divestiture, as applicable. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses.

	Continuing Operations
	Three Months Ended March 31,
							Increase
Selected Operating Statistics	2016			2015			(Decrease)
Hospital Operations and other
Number of hospitals (at end of period)		80			80		—	(1)
Total admissions		211,799			208,333		1.7	%
Adjusted patient admissions(2)		362,819			349,097		3.9	%
Paying admissions (excludes charity and uninsured)		201,436			197,383		2.1	%
Charity and uninsured admissions		10,363			10,950		(5.4)	%
Emergency department visits		925,972			875,077		5.8	%
Total surgeries		132,584			121,403		9.2	%
Patient days — total		1,010,514			975,912		3.5	%
Adjusted patient days(2)		1,714,369			1,618,516		5.9	%
Average length of stay (days)		4.77			4.68		1.9	%
Average licensed beds		21,524			20,823		3.4	%
Utilization of licensed beds(3)		51.6	%		52.1	%	(0.5)	%(1)
Total visits		2,146,618			1,994,573		7.6	%
Paying visits (excludes charity and uninsured)		1,984,515			1,837,376		8.0	%
Charity and uninsured visits		162,103			157,197		3.1	%
Ambulatory Care
Total consolidated facilities (at end of period)		211			64		147	(1)
Total cases		444,239			150,771		194.6	%

(1) The change is the difference between the 2016 and 2015 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions increased by 3,466, or 1.7%, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015. Total surgeries increased by 9.2% in the three months ended March 31, 2016 compared

25

to the same period in 2015. Our emergency department visits increased 5.8% in the three months ended March 31, 2016 compared to the same period in the prior year. Our volumes were positively impacted by acquisitions, as well as, we believe, incremental market share we generated through improved physician alignment and service line expansion, insurance coverage for a greater number of individuals, and a strengthening economy.

	Continuing Operations
	Three Months Ended March 31,
					Increase
Revenues	2016		2015		(Decrease)
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787	13.2	%
Hospital Operations and other
Revenues from charity and the uninsured	$	223	$	264	(15.5)	%
Net inpatient revenues(1)	$	2,781	$	2,691	3.3	%
Net outpatient revenues(1)	$	1,514	$	1,412	7.2	%
Ambulatory Care revenues	$	429	$	91	371.4	%
Conifer revenues	$	385	$	342	12.6	%

(1) Net inpatient revenues and net outpatient revenues are components of net operating revenues. Net inpatient revenues include self-pay revenues of $78 million and $106 million for the three months ended March 31, 2016 and 2015, respectively. Net outpatient revenues include self-pay revenues of $145 million and $158 million for the three months ended March 31, 2016 and 2015, respectively.

Net operating revenues before provision for doubtful accounts increased by $633 million, or 13.2%, in the three months ended March 31, 2016 compared to the same period in 2015, primarily due to acquisitions, increases in our outpatient volumes and  improved managed care pricing. Net operating revenues before provision for doubtful accounts in the three months ended March 31, 2016 included $57 million of net revenues from the California provider fee program described in our Annual Report compared to $46 million during the three months ended March 31, 2015.

	Continuing Operations
	Three Months Ended March 31,
							Increase
Provision for Doubtful Accounts	2016			2015			(Decrease)
Provision for doubtful accounts	$	376		$	363		3.6	%
Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts		6.9	%		7.6	%	(0.7)	%(1)

(1) The change is the difference between the 2016 and 2015 amounts shown.

Provision for doubtful accounts increased by $13 million, or 3.6%, in the three months ended March 31, 2016 compared to the same period in 2015, and provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 6.9% and 7.6% for the three months ended March 31, 2016 and 2015, respectively. The decrease in the provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts primarily related to the impact of the $41 million decrease in revenues from charity and the uninsured. Our accounts receivable days outstanding (“AR Days”) from continuing operations were 50.6 days at March 31, 2016 and 49.5 days at December 31, 2015, within our target of less than 55 days.

26

	Continuing Operations
	Three Months Ended March 31,
					Increase
Selected Operating Expenses	2016		2015		(Decrease)
Hospital Operations and other
Salaries, wages and benefits	$	2,017	$	1,908	5.7	%
Supplies		725		670	8.2	%
Other operating expenses		1,073		1,005	6.8	%
Total	$	3,815	$	3,583	6.5	%
Ambulatory Care
Salaries, wages and benefits	$	146	$	24	508.3	%
Supplies		86		17	405.9	%
Other operating expenses		86		21	309.5	%
Total	$	318	$	62	412.9	%
Conifer
Salaries, wages and benefits	$	239	$	193	23.8	%
Other operating expenses		83		67	23.9	%
Total	$	322	$	260	23.8	%
Total
Salaries, wages and benefits	$	2,402	$	2,125	13.0	%
Supplies		811		687	18.0	%
Other operating expenses		1,242		1,093	13.6	%
Total	$	4,455	$	3,905	14.1	%
Rent/lease expense(1)
Hospital Operations and other	$	61	$	54	13.0	%
Ambulatory Care		17		7	142.9	%
Conifer		4		3	33.3	%
Total	$	82	$	64	28.1	%

(1) Included in other operating expenses.

	Continuing Operations
	Three Months Ended March 31,
					Increase
Selected Operating Expenses per Adjusted Patient Admission	2016		2015		(Decrease)
Hospital Operations and other
Salaries, wages and benefits per adjusted patient admission(1)	$	5,559	$	5,466	1.7	%
Supplies per adjusted patient admission(1)		1,998		1,919	4.1	%
Other operating expenses per adjusted patient admission(1)		2,980		2,899	2.8	%
Total per adjusted patient admission	$	10,537	$	10,284	2.5	%

(1) Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits per adjusted patient admission increased 1.7% in the three months ended March 31, 2016 compared to the same period in 2015. This change is primarily due to annual merit increases for certain of our employees and increased employee health benefits costs in the three months ended March 31, 2016 compared to the three months ended March 31, 2015.

Supplies expense per adjusted patient admission increased 4.1% in the three months ended March 31, 2016 compared to the three months ended March 31, 2015. The change in supplies expense was primarily attributable to higher costs for pharmaceuticals and cardiology supplies, and volume growth in our higher acuity supply-intensive surgical services.

Other operating expenses per adjusted patient admission increased by 2.8% in the three months ended March 31, 2016 compared to the three months ended March 31, 2015. This increase is due to higher contracted services

27

and medical fees, as well as increased costs associated with our health plans due to an increase in covered lives, which costs were offset by increased health plan revenues. Malpractice expense was $2 million higher in the 2016 period compared to the 2015 period. The 2016 period included an unfavorable adjustment of approximately $12 million due to a 55 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities compared to an unfavorable adjustment of approximately $5 million as a result of a 26 basis point decrease in the interest rate in the 2015 period.

LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $728 million at March 31, 2016 compared to $356 million at December 31, 2015.

Significant cash flow items in the three months ended March 31, 2016 included:

· Proceeds from sales of facilities and other assets of $573 million;

· Capital expenditures of $208 million;

· Purchases of businesses for $29 million;

· $117 million in aggregate annual 401(k) contributions and $150 million in annual incentive compensation payments, which were accrued as compensation expense in 2015; and

· Interest payments of $132 million.

Net cash provided by operating activities was $147 million in the three months ended March 31, 2016 compared to $57 million net cash used in operating activities in the three months ended March 31, 2015. Key positive and negative factors contributing to the change between the 2016 and 2015 periods include the following:

· Increased income from continuing operations before income taxes of $84 million, excluding net gain on sales of investments, investment earnings (loss), gain (loss) from early extinguishment of debt, interest expense, gains on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, and depreciation and amortization in the three months ended March 31, 2016 compared to the three months ended March 31, 2015;

· $44 million less cash used by the change in accounts receivable, net of provision for doubtful accounts, in the 2016 period;

· Approximately $132 million of additional net cash proceeds in the 2016 period related to supplemental Medicaid programs, primarily in California and Texas;

· Higher aggregate annual 401(k) matching contributions and annual incentive compensation payments of $18 million and $9 million,  respectively, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015;

· An increase of $36 million in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements; and

· Higher interest payments of $15 million.

Cash flows from operating activities in the first quarter of the calendar year are usually lower than in subsequent quarters of the year, primarily due to the timing of certain working capital requirements during the first quarter, including our annual 401(k) matching contributions and annual incentive compensation payments.

28

FORWARD-LOOKING STATEMENTS

The information in this report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements. These forward-looking statements represent management’s current expectations, based on currently available information, as to the outcome and timing of future events. They involve known and unknown risks, uncertainties and other factors — many of which we are unable to predict or control — that may cause our actual results, performance or achievements, or healthcare industry results, to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

When considering forward-looking statements, a reader should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in our Annual Report or this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to update any information contained in a forward-looking statement or any forward-looking statement in its entirety and, therefore, disclaim any resulting liability for potentially related damages.

All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

SOURCES OF REVENUE

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and self-pay patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).

The table below shows the sources of net patient revenues before provision for doubtful accounts for our Hospital Operations and other segment, expressed as percentages of net patient revenues before provision for doubtful accounts from all sources:

	Three Months Ended
	March 31,
					Increase
Net Patient Revenues from:	2016		2015		(Decrease)(1)
Medicare	20.0	%	21.9	%	(1.9)	%
Medicaid	8.7	%	9.4	%	(0.7)	%
Managed care	61.1	%	58.6	%	2.5	%
Indemnity, self-pay and other	10.2	%	10.1	%	0.1	%

(1) The increase (decrease) is the difference between the 2016 and 2015 percentages shown.

29

Our payer mix on an admissions basis for our Hospital Operations and other segment, expressed as a percentage of total admissions from all sources, is shown below:

	Three Months Ended
	March 31,
					Increase
Admissions from:	2016		2015		(Decrease)(1)
Medicare	27.2	%	28.0	%	(0.8)	%
Medicaid	7.3	%	8.2	%	(0.9)	%
Managed care	58.1	%	56.3	%	1.8	%
Indemnity, self-pay and other	7.4	%	7.5	%	(0.1)	%

(1) The increase (decrease) is the difference between the 2016 and 2015 percentages shown.

GOVERNMENT PROGRAMS

The Centers for Medicare and Medicaid Services (“CMS”) is the single largest payer of healthcare services in the United States. Approximately 129 million Americans rely on healthcare benefits through Medicare, Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and directed by CMS, an agency of the U.S. Department of Health and Human Services (“HHS”). Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets. Medicaid is administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage.

Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-service payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-service Medicare special needs plans and Medicare medical savings account plans. The major components of our net patient revenues from continuing operations of our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan for the three months ended March 31, 2016 and 2015 are set forth in the following table:

	Three Months Ended
	March 31,
Revenue Descriptions	2016		2015
Medicare severity-adjusted diagnosis-related group — operating	$	474	$	457
Medicare severity-adjusted diagnosis-related group — capital		43		42
Outliers		22		18
Outpatient		222		234
Disproportionate share		78		88
Direct Graduate and Indirect Medical Education(1)		64		67
Other(2)		(17)		11
Adjustments for prior-year cost reports and related valuation allowances		13		22
Total Medicare net patient revenues	$	899	$	939

(1) Includes Indirect Medical Education revenues earned by our children’s hospitals under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS.

(2) The other revenue category includes inpatient psychiatric units, inpatient rehabilitation units, one long-term acute care hospital, other revenue adjustments, and adjustments related to the estimates for current-year cost reports and related valuation allowances.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

30

Medicaid

Medicaid programs and the corresponding reimbursement methodologies are administered by the states and vary from state to state and from year to year. Estimated revenues under various state Medicaid programs, including state-funded managed care Medicaid programs, constituted approximately 19.0% and 19.1% of total net patient revenues before provision for doubtful accounts of our continuing general hospitals for the three months ended March 31, 2016 and 2015, respectively. We also receive DSH and other supplemental revenues under various state Medicaid programs. For the three months ended March 31, 2016 and 2015, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $227 million and $247 million, respectively.

Several states in which we operate face budgetary challenges that have resulted, and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted provider fee programs or received waivers under Section 1115 of the Social Security Act. Under a Medicaid waiver, the federal government waives certain Medicaid requirements, thereby giving states flexibility in the operation of their Medicaid program to allow states to test new approaches and demonstration projects to improve care. Generally the Section 1115 waivers are for a period of five years with an option to extend the waiver for three additional years. Continuing pressure on state budgets and other factors could result in future reductions to Medicaid payments, payment delays or additional taxes on hospitals.

Because we cannot predict what actions the federal government or the states may take under existing legislation and future legislation to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid section 1115 waivers, we are unable to assess the effect that any such legislation might have on our business, but the impact on our future financial position, results of operations or cash flows could be material.

Medicaid-related patient revenues from continuing operations recognized by our Hospital Operations and other segment from Medicaid-related programs in the states in which our hospitals are located, as well as from Medicaid programs in neighboring states, for the three months ended March 31, 2016 and 2015 are set forth in the table below:

	Three Months Ended
	March 31,
	2016				2015
			Managed				Managed
Hospital Location	Medicaid		Medicaid		Medicaid		Medicaid
California	$	104	$	103	$	80	$	94
Michigan		98		73		85		77
Texas		52		61		94		59
Alabama		27		—		3		—
Florida		22		42		24		41
Georgia		19		9		17		9
Pennsylvania		19		51		17		48
Illinois		18		18		28		10
Massachusetts		8		14		9		12
Arizona		4		55		(2)		26
South Carolina		2		9		4		9
Tennessee		1		8		2		8
North Carolina		—		—		6		1
Missouri		(1)		—		18		4
	$	373	$	443	$	385	$	398

31

Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems are provided below.

Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems

Under Medicare law, CMS is required to annually update certain rules governing the inpatient prospective payment systems (“IPPS”). The updates generally become effective October 1, the beginning of the federal fiscal year. On April 18, 2016, CMS issued Proposed Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2017 Rates (“Proposed IPPS Rule”). The Proposed IPPS Rule includes the following payment and policy changes:

· A market basket increase of 2.8% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record (“EHR”) technology (hospitals that do not report specified quality measure data and/or are not meaningful users of EHR technology will receive a reduced market basket increase); CMS is also proposing certain adjustments to the estimated 2.8% market basket increase and the outlier baseline that result in a net operating payment update of 0.65% (before budget neutrality adjustments), including:

· Market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.5%, respectively;

· A documentation and coding recoupment reduction of 1.5% as required by the American Taxpayer Relief Act of 2012;

· Prospective reversal of the 0.2% reduction related to the two-midnights rule that was first imposed in federal fiscal year (“FFY”) 2014;

· A one-time increase of 0.6% to reverse the 0.2% two-midnights rule reductions imposed in FFYs 2014 through 2016; and

· A 0.2% reduction in the FFY 2016 estimated outlier baseline of 5.3% to ensure that FFY 2017 outlier payments do not exceed 5.1% of total IPPS payments.

· Updates to the factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”) payments;

· A 1.73% net increase in the capital federal MS-DRG rate;

· An increase in the cost outlier threshold from $22,544 to $23,681; and

· A proposed three-year transition beginning in FFY 2018 to use uncompensated care to determine the distribution of the UC-DSH payments.

CMS projects that the combined impact of the payment and policy changes in the Proposed IPPS Rule will yield an average 0.6% increase in operating MS-DRG payments for hospitals in large urban areas (populations over one million) in FFY 2016. The proposed payment and policy changes affecting operating MS-DRG payments and other proposals, notably those affecting Medicare UC-DSH payments, would result in an estimated 0.1% increase in our annual IPPS payments, which yields an estimated decrease of approximately $2 million in our annual Medicare IPPS payments. Because of the uncertainty regarding factors that may influence our future IPPS payments by individual hospital, including legislative action, admission volumes, length of stay and case mix, as well as potential changes to the proposed rule, we cannot provide any assurances regarding our estimate of the impact of the proposed changes.

32

PRIVATE INSURANCE

Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contracted healthcare providers for non-emergency care.

PPOs generally offer limited benefits to members who use non-contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient revenues during the three months ended March 31, 2016 and 2015 was $2.6 billion and $2.4 billion, respectively. Approximately 62% of our managed care net patient revenues for the three months ended March 31, 2016 was derived from our top ten managed care payers. National payers generated approximately 44% of our total net managed care revenues. The remainder comes from regional or local payers. At both March 31, 2016 and December 31, 2015, approximately 59% of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at March 31, 2016, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $15 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-house and discharged-not-final-billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our operating income. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefitted from solid year-over-year aggregate managed care pricing improvements for several years, we have seen these improvements moderate recently, and we believe the moderation could continue in future years. In the three months

33

ended March 31, 2016, our commercial managed care net inpatient revenue per admission from our acute care hospitals was approximately 76% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans.

Indemnity

An indemnity-based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

SELF-PAY PATIENTS

Self-pay patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our self-pay patients are admitted through our hospitals’ emergency departments and often require high-acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self-pay accounts pose significant collectability problems. At both March 31, 2016 and December 31, 2015, approximately 5% of our net accounts receivable for our Hospital Operations and other segment were due from self-pay patients. Further, a significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. We provide revenue cycle management services through our Conifer subsidiary, which is subject to various laws, rules and regulations regarding consumer finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, in Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our provision for doubtful accounts in the aggregate, this is not the case at all hospitals. As a result, we have been increasing our focus on targeted initiatives that concentrate on non-emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self-pay accounts, as well as co-pay and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address this challenge. For example, our Compact with Uninsured Patients (“Compact”) is designed to offer managed care-style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. A significant portion of those charges had previously been written down in our provision for doubtful accounts. Under the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. Generally, our method of measuring the estimated costs uses adjusted self-pay/charity patient days multiplied by selected operating expenses (which include salaries, wages and benefits, supplies and other operating expenses) per adjusted patient day. The adjusted self-pay/charity patient days represents actual self-pay/charity patient days adjusted to include self-pay/charity outpatient

34

services by multiplying actual self-pay/charity patient days by the sum of gross self-pay/charity inpatient revenues and gross self-pay/charity outpatient revenues and dividing the results by gross self-pay/charity inpatient revenues. The following table shows our estimated costs (based on selected operating expenses) of caring for self-pay patients and charity care patients, as well as revenues attributable to Medicaid DSH and other supplemental revenues we recognized, in the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016		2015
Estimated costs for:
Self-pay patients	$	165	$	164
Charity care patients	$	44	$	36
Medicaid DSH and other supplemental revenues	$	227	$	247

The expansion of health insurance coverage has resulted in an increase in the number of patients using our facilities who have either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of states to expand Medicaid coverage and for persons living in the country illegally who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.

35

RESULTS OF OPERATIONS

The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues:
General hospitals	$	4,302	$	4,117
Other operations		1,118		670
Net operating revenues before provision for doubtful accounts		5,420		4,787
Less provision for doubtful accounts		376		363
Net operating revenues		5,044		4,424
Equity in earnings of unconsolidated affiliates		24		4
Operating expenses:
Salaries, wages and benefits		2,402		2,125
Supplies		811		687
Other operating expenses, net		1,242		1,093
Electronic health record incentives		—		(6)
Depreciation and amortization		212		207
Impairment and restructuring charges, and acquisition-related costs		28		29
Litigation and investigation costs		173		3
Gains on sales, consolidation and deconsolidation of facilities		(147)		—
Operating income	$	347	$	290

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	100.0	%	100.0	%
Equity in earnings of unconsolidated affiliates	0.5	%	0.1	%
Operating expenses:
Salaries, wages and benefits	47.6	%	48.0	%
Supplies	16.1	%	15.5	%
Other operating expenses, net	24.6	%	24.7	%
Electronic health record incentives	—	%	(0.2)	%
Depreciation and amortization	4.2	%	4.7	%
Impairment and restructuring charges, and acquisition-related costs	0.6	%	0.7	%
Litigation and investigation costs	3.4	%	0.1	%
Gains on sales, consolidation and deconsolidation of facilities	(2.9)	%	—	%
Operating income	6.9	%	6.6	%

Net operating revenues of our general hospitals include inpatient and outpatient revenues for services provided by facilities in our Hospital Operations and other segment, as well as nonpatient revenues (e.g., rental income, management fee revenue, and income from services such as cafeterias, gift shops and parking) and other miscellaneous revenue. Net operating revenues of other operations primarily consist of revenues from (1) physician practices, (2) a long-term acute care hospital, (3) our Ambulatory Care segment, (4) services provided by our Conifer subsidiary to third parties and (5) our health plans. Revenues from our general hospitals represented approximately 79% and 86% of our total net operating revenues before provision for doubtful accounts for the three months ended March 31, 2016 and 2015, respectively.

Net operating revenues from our other operations were $1.118 billion and $670 million in the three months ended March 31, 2016 and 2015, respectively. The increase in net operating revenues from other operations during 2016 primarily relates to revenue cycle services provided by our Conifer subsidiary, as well as revenues from our USPI joint venture and Aspen acquisition, our health plans and physician practices. Equity earnings of unconsolidated affiliates

36

were $24 million and $4 million for the three months ended March 31, 2016 and 2015, respectively. The increase in equity earnings of unconsolidated affiliates in the 2016 period compared to the 2015 period primarily related to our USPI joint venture.

The following table shows selected operating expenses of our three reportable business segments. Information for our Hospital Operations and other segment is presented on a same-hospital basis, which includes the results of our same 72 hospitals and six health plans operated throughout the three months ended March 31, 2016 and 2015. The results of (i) Hi-Desert Medical Center, which we began operating on July 15, 2015, (ii) our Carondelet Heath Network joint venture, in which we acquired a majority interest on August 31, 2015, (iii) Saint Louis University Hospital, which we divested on August 31, 2015, (iv) our joint venture with Baptist Health System, Inc., which we formed on October 2, 2015, (v) DMC Surgery Hospital, which we closed in October 2015, (vi) Central Carolina Hospital and Frye Regional Medical Center, which we divested effective January 1, 2016, and (vii) our North Texas hospitals, in which we divested a controlling interest effective January 1, 2016, but continue to operate,are excluded.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Selected Operating Expenses	2016		2015		(Decrease)
Hospital Operations and other — Same-Hospital
Salaries, wages and benefits	$	1,868	$	1,798	3.9	%
Supplies		660		616	7.1	%
Other operating expenses		999		910	9.8	%
Total	$	3,527	$	3,324	6.1	%
Ambulatory Care
Salaries, wages and benefits	$	146	$	24	508.3	%
Supplies		86		17	405.9	%
Other operating expenses		86		21	309.5	%
Total	$	318	$	62	412.9	%
Conifer
Salaries, wages and benefits	$	239	$	193	23.8	%
Other operating expenses		83		67	23.9	%
Total	$	322	$	260	23.8	%
Rent/lease expense(1)
Hospital Operations and other	$	52	$	48	8.3	%
Ambulatory Care		17		7	142.9	%
Conifer		4		3	33.3	%
Total	$	73	$	58	25.9	%

(1) Included in other operating expenses.

Results of Operations by Segment

Our operations are reported under three segments: Hospital Operations and other, which is focused on operating acute care hospitals, ancillary outpatient facilities, freestanding emergency departments, physician practices and health plans; Ambulatory Care, which is comprised of our USPI joint venture’s ambulatory surgery centers, urgent care centers, imaging centers and short-stay surgical hospitals, as well as Aspen’s hospitals and clinics; and Conifer, which operates revenue cycle management and patient communication and engagement services businesses.

Hospital  Operationsand  other  Segment

The following tables show operating statistics of our continuing operations hospitals on a same-hospital basis, which includes the results of our same 72 hospitals and six health plans operated throughout the three months ended March 31, 2016 and 2015. The results of (i) Hi-Desert Medical Center, which we began operating on July 15, 2015, (ii) our Carondelet Heath Network joint venture, in which we acquired a majority interest on August 31, 2015, (iii) Saint Louis University Hospital, which we divested on August 31, 2015, (iv) our joint venture with Baptist Health

37

System, Inc., which we formed on October 2, 2015, (v) DMC Surgery Hospital, which we closed in October 2015, (vi) Central Carolina Hospital and Frye Regional Medical Center, which we divested effective January 1, 2016, and (vii) our North Texas hospitals, in which we divested a controlling interest effective January 1, 2016, but continue to operate, are excluded.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Admissions, Patient Days and Surgeries	2016		2015		(Decrease)
Number of hospitals (at end of period)	72		72		—	(1)
Total admissions	193,980		194,143		(0.1)	%
Adjusted patient admissions(2)	330,575		323,577		2.2	%
Paying admissions (excludes charity and uninsured)	184,436		184,225		0.1	%
Charity and uninsured admissions	9,544		9,918		(3.8)	%
Admissions through emergency department	125,004		124,492		0.4	%
Paying admissions as a percentage of total admissions	95.1	%	94.9	%	0.2	%(1)
Charity and uninsured admissions as a percentage of total admissions	4.9	%	5.1	%	(0.2)	%(1)
Emergency department admissions as a percentage of total admissions	64.4	%	64.1	%	0.3	%(1)
Surgeries — inpatient	50,563		50,447		0.2	%
Surgeries — outpatient	66,467		62,949		5.6	%
Total surgeries	117,030		113,396		3.2	%
Patient days — total	911,651		909,116		0.3	%
Adjusted patient days(2)	1,537,812		1,499,932		2.5	%
Average length of stay (days)	4.70		4.68		0.4	%
Licensed beds (at end of period)	19,293		19,393		(0.5)	%
Average licensed beds	19,288		19,390		(0.5)	%
Utilization of licensed beds(3)	52.5	%	52.1	%	0.4	%(1)

(1) The change is the difference between 2016 and 2015 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Outpatient Visits	2016		2015		(Decrease)
Total visits	1,949,159		1,852,780		5.2	%
Paying visits (excludes charity and uninsured)	1,804,947		1,710,661		5.5	%
Charity and uninsured visits	144,212		142,119		1.5	%
Emergency department visits	726,730		688,242		5.6	%
Surgery visits	66,467		62,949		5.6	%
Paying visits as a percentage of total visits	92.6	%	92.3	%	0.3	%(1)
Charity and uninsured visits as a percentage of total visits	7.4	%	7.7	%	(0.3)	%(1)

(1) The change is the difference between 2016 and 2015 amounts shown.

38

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Revenues	2016		2015		(Decrease)
Net operating revenues	$	3,940	$	3,701	6.5	%
Revenues from charity and the uninsured	$	223	$	244	(8.6)	%
Net inpatient revenues(1)	$	2,616	$	2,501	4.6	%
Net outpatient revenues(1)	$	1,400	$	1,289	8.6	%

(1) Net inpatient revenues and net outpatient revenues are components of net operating revenues. Net inpatient revenues include self-pay revenues of $88 million and $100 million for the three months ended March 31, 2016 and 2015, respectively. Net outpatient revenues include self-pay revenues of $135 million and $144 million for the three months ended March 31, 2016 and 2015, respectively.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Revenues on a Per Admission, Per Patient Day and Per Visit Basis	2016		2015		(Decrease)
Net inpatient revenue per admission	$	13,486	$	12,882	4.7	%
Net inpatient revenue per patient day	$	2,870	$	2,751	4.3	%
Net outpatient revenue per visit	$	718	$	696	3.2	%
Net patient revenue per adjusted patient admission(1)	$	12,149	$	11,713	3.7	%
Net patient revenue per adjusted patient day(1)	$	2,612	$	2,527	3.4	%

(1) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
							Increase
Provision for Doubtful Accounts	2016			2015			(Decrease)
Provision for doubtful accounts	$	351		$	326		7.7	%
Provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts		8.2	%		8.1	%	0.1	%(1)

(1) The change is the difference between 2016 and 2015 amounts shown.

	Same-Hospital
	Continuing Operations
	Three Months Ended March 31,
					Increase
Selected Operating Expenses	2016		2015		(Decrease)
Hospital Operations and other — Same-Hospital
Salaries, wages and benefits as a percentage of net operating revenues	47.4	%	48.6	%	(1.2)	%(1)
Supplies as a percentage of net operating revenues	16.8	%	16.6	%	0.2	%(1)
Other operating expenses as a percentage of net operating revenues	25.4	%	24.6	%	0.8	%(1)

(1) The change is the difference between 2016 and 2015 amounts shown.

Revenues

Same-hospital net operating revenues increased $239 million, or 6.5%, during the three months ended March 31, 2016 compared to the three months ended March 31, 2015. The increase in same-hospital net operating revenues in the 2016 period is primarily due to volume growth in higher acuity inpatient services, higher outpatient volumes, improved terms of our managed care contracts and an increase in our other operations revenues. Same-hospital net inpatient revenues increased $115 million, or 4.6%, and same-hospital adjusted admissions increased 2.2% in the three months ended March 31, 2016 compared to the same period in 2015. We believe our volumes were positively impacted by incremental market share we generated through improved physician alignment and service line expansion,

39

insurance coverage for a greater number of individuals, and a strengthening economy. Same-hospital net inpatient revenue per admission increased 4.7%, primarily due to the improved terms of our managed care contracts and volume growth in higher acuity service lines, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015. Same-hospital net outpatient revenues increased $111 million, or 8.6%, and same-hospital outpatient visits increased 5.2% in the three months ended March 31, 2016 compared to the same period in 2015. Growth in outpatient revenues and volumes was primarily driven by improved terms of our managed care contracts and increased outpatient volume levels associated with our outpatient development program. Same-hospital net outpatient revenue per visit increased 3.2% in the three months ended March 31, 2016 compared to the three months ended March 31, 2015 primarily due to the improved terms of our managed care contracts.

Provision for Doubtful Accounts

Same-hospital provision for doubtful accounts as a percentage of net operating revenues before provision for doubtful accounts was 8.2% and 8.1% for the three months ended March 31, 2016 and 2015, respectively. The table below shows the consolidated net accounts receivable and allowance for doubtful accounts by payer at March 31, 2016 and December 31, 2015.

	March 31, 2016						December 31, 2015
	Accounts						Accounts
	Receivable						Receivable
	Before						Before
	Allowance		Allowance				Allowance		Allowance
	for Doubtful		for Doubtful				for Doubtful		for Doubtful
	Accounts		Accounts		Net		Accounts		Accounts		Net
Medicare	$	400	$	—	$	400	$	360	$	—	$	360
Medicaid		85		—		85		70		—		70
Net cost report settlements payable and valuation allowances		(47)		—		(47)		(42)		—		(42)
Managed care		1,808		142		1,666		1,715		126		1,589
Self-pay uninsured		459		403		56		509		436		73
Self-pay balance after insurance		228		155		73		208		142		66
Estimated future recoveries from accounts assigned to our Conifer subsidiary		146		—		146		144		—		144
Other payers		434		176		258		442		166		276
Total Hospital Operations and other		3,513		876		2,637		3,406		870		2,536
Ambulatory Care		192		25		167		182		17		165
Total discontinued operations		3		—		3		3		—		3
	$	3,708	$	901	$	2,807	$	3,591	$	887	$	2,704

A significant portion of our provision for doubtful accounts relates to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. Collection of accounts receivable has been a key area of focus, particularly over the past several years. At March 31, 2016, our collection rate on self-pay accounts was approximately 27.3%. Our self-pay collection rate includes payments made by patients, including co-pays and deductibles paid by patients with insurance. Based on our accounts receivable from self-pay patients and co-pays and deductibles owed to us by patients with insurance at March 31, 2016, a 10% decrease or increase in our self-pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to provision for doubtful accounts of approximately $9 million.

Payment pressure from managed care payers also affects our provision for doubtful accounts. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated collection rate from managed care payers was approximately 98.4% at March 31, 2016.

40

We manage our provision for doubtful accounts using hospital-specific goals and benchmarks such as (1) total cash collections, (2) point-of-service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.684 billion and $2.578 billion at March 31, 2016 and December 31, 2015, respectively, excluding cost report settlements payable and valuation allowances of $47 million and $42 million at March 31, 2016 and December 31, 2015, respectively:

	March 31, 2016
							Indemnity,
					Managed		Self-Pay
	Medicare		Medicaid		Care		and Other		Total
0-60 days	91	%	65	%	64	%	26	%	62	%
61-120 days	5	%	17	%	19	%	16	%	13	%
121-180 days	2	%	7	%	9	%	10	%	7	%
Over 180 days	2	%	11	%	8	%	48	%	18	%
Total	100	%	100	%	100	%	100	%	100	%

	December 31, 2015
							Indemnity,
					Managed		Self-Pay
	Medicare		Medicaid		Care		and Other		Total
0-60 days	90	%	65	%	64	%	27	%	62	%
61-120 days	6	%	16	%	16	%	19	%	15	%
121-180 days	2	%	6	%	7	%	11	%	7	%
Over 180 days	2	%	13	%	13	%	43	%	16	%
Total	100	%	100	%	100	%	100	%	100	%

At March 31, 2016, we had a cumulative total of patient account assignments to our Conifer subsidiary of approximately $2.7 billion related to our continuing operations, but excluding our newly acquired hospitals. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts; however, an estimate of future recoveries from all the accounts assigned to our Conifer subsidiary is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s Medicaid Eligibility Program (“MEP”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the MEP, with appropriate contractual allowances recorded. At the present time, our newly acquired facilities are beginning to implement this program. Based on recent trends, approximately 94% of all accounts in the MEP are ultimately approved for benefits under a government program, such as Medicaid. The following table shows the approximate amount of accounts receivable in the MEP still awaiting determination of eligibility under a government program at March 31, 2016 and December 31, 2015 by aging category for the hospitals currently in the program.

	March 31,		December 31,
	2016		2015
0-60 days	$	84	$	86
61-120 days		14		14
121-180 days		8		7
Over 180 days		16		18
Total	$	122	$	125

Salaries, Wages and Benefits

Same-hospital salaries, wages and benefits as a percentage of net operating revenues decreased 1.2% to 47.4% in the three months ended March 31, 2016 compared to 48.6% for the same period in 2015. While same-hospital net

41

operating revenues increased 6.5% during the three months ended March 31, 2016 compared to the three months ended March 31, 2015, as previously discussed, same-hospital salaries, wages and benefits increased by only 3.9% in the three months ended March 31, 2016 compared to the 2015 period. This increase in same-hospital salaries, wages and benefits was primarily due to annual merit increases for certain of our employees, and increased employee health benefits costs. Salaries, wages and benefits expense for the three months ended March 31, 2016 and 2015 included stock-based compensation expense of $13 million and $18 million, respectively.

At March 31, 2016, approximately 22% of the employees in our Hospital Operations and other segment were represented by labor unions. There were no unionized employees in our Ambulatory Care segment, and less than 1% of Conifer’s employees belong to a union. Unionized employees – primarily registered nurses and service and maintenance workers – are located at 37 of our hospitals, the majority of which are in California, Florida and Michigan. We currently have five expired contracts and are negotiating renewals under extension agreements. We are also negotiating first contracts at five hospitals and one physician practice where employees recently selected union representation. At this time, we are unable to predict the outcome of the negotiations, but increases in salaries, wages and benefits could result from these agreements. Furthermore, there is a possibility that strikes could occur during the negotiation process, which could increase our labor costs and have an adverse effect on our patient admissions and net operating revenues. Future organizing activities by labor unions could increase our level of union representation in 2016.

Supplies

Same-hospital supplies expense as a percentage of net operating revenues increased 0.2% to 16.8% in the three months ended March 31, 2016 compared to 16.6% for the same period in 2015. The increase in supplies expense was primarily attributable to higher costs for pharmaceuticals and cardiology supplies, as well as volume growth in our higher acuity supply-intensive surgical services.

We strive to control supplies expense through product standardization, contract compliance, improved utilization, bulk purchases and operational improvements. The items of current cost reduction focus continue to be cardiac stents and pacemakers, orthopedics and implants, and high-cost pharmaceuticals. We also utilize group-purchasing strategies and supplies-management services in an effort to reduce costs.

Other Operating Expenses, Net

Same-hospital other operating expenses as a percentage of net operating revenues increased 0.8% to 25.4% in the three months ended March 31, 2016 compared to 24.6% for the same period in 2015. The increase in other operating expenses was primarily due to:

· additional medical fees of $15 million;

· increased costs associated with our health plans due to an increase in covered lives of $20 million, which costs were offset by increased health plan revenues; and

· increased costs of contracted services of $37 million.

Same-hospital malpractice expense in the 2016 period included an unfavorable adjustment of approximately $12 million due to a 55 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities compared to an unfavorable adjustment of approximately $5 million as a result of a 26 basis point decrease in the interest rate in the 2015 period.

Ambulatory  Care  Segment

On June 16, 2015, we completed the transaction that combined our freestanding ambulatory surgery and imaging center assets with the short-stay surgical facility assets of USPI into our new USPI joint venture, and we acquired Aspen, which operates nine private short-stay surgical hospitals and clinics in the United Kingdom, thereby

42

forming our new Ambulatory Care separate reportable business segment. The results of our USPI joint venture and Aspen are included in the financial and statistical information provided only for the period from acquisition to March 31, 2016.

Our USPI joint venture operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity. We operate facilities on a day-to-day basis through management services contracts. Our sources of earnings from each facility consist of:

· management services revenues, computed as a percentage of each facility’s net revenues (often net of bad debt expense); and

· our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by us.

Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. In many of the facilities our Ambulatory Care segment operates (122 of 335 at March 31, 2016), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. We control 213 of the facilities we operate and account for these investments as consolidated subsidiaries.

Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than us is classified within “net income attributable to noncontrolling interests.”

For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:

· equity in earnings of unconsolidated affiliates—our share of the net income of each facility, which is based on the facility’s net income and the percentage of the facility’s outstanding equity interests owned by us; and

· management and administrative services revenues, which is included in our net operating revenues—income we earn in exchange for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less bad debt expense.

Our Ambulatory Care operating income is driven by the performance of all facilities we operate and by our ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 64% of our facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses.

Three Months Ended March 31, 2016 Compared to Three Months Ended March 31, 2015

The following table summarizes certain consolidated statements of operations items for the periods indicated:

	Three Months Ended
	March 31,
Ambulatory Care Results of Operations	2016		2015
Net operating revenues	$	429	$	91
Equity in earnings of unconsolidated affiliates		25		—
Operating expenses, excluding depreciation and amortization		318		62
Depreciation and amortization		25		4
Operating income	$	111	$	25

43

Our Ambulatory Care net operating revenues increased by $338 million, or 371.4%, for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. The growth in revenues was primarily driven by increases from acquisitions of $334 million.

Salaries, wages and benefits expense increased by $122 million, or 508.3%, for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. This increase was primarily driven by salaries, wages and benefits expense from acquisitions of $120 million.

Supplies expense increased by $69 million, or 405.9%, for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. This increase was primarily driven by supplies expense from acquisitions of $68 million.

Other operating expenses increased by $65 million, or 309.5%, for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. This increase was driven by other operating expenses from acquisitions of $65 million.

Facility Growth

The following table summarizes the changes in our same-facility revenue year-over-year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of our unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

	Three Months Ended
Ambulatory Care Facility Growth	March 31, 2016
Net revenues	11.0	%
Cases	8.6	%
Net revenue per case	2.2	%

Joint Ventures with Health System Partners

During the three months ended June 30, 2015, we established our new Ambulatory Care segment as a result of our joint venture with USPI and our purchase of Aspen. USPI’s business model is to jointly own its facilities with local physicians and not-for-profit health systems. Accordingly, as of March 31, 2016, the majority of facilities in our Ambulatory Care segment are operated in this model.

	Three Months Ended
Ambulatory Care Facilities with Health System Partners	March 31, 2016
Facilities:
With a health system partner	179
Without a health system partner	156
Total facilities operated	335
Change from December 31, 2015
Acquisitions	2
De novo	1
Dispositions/Mergers	(1)
Total increase in number of facilities operated	2

Conifer  Segment

Our Conifer subsidiary generated net operating revenues of $385 million and $342 million during the three months ended March 31, 2016 and 2015, respectively, a portion of which was eliminated in consolidation as described in

44

Note 16 to the Condensed Consolidated Financial Statements. The increase in the revenue from third-party customers, which is not eliminated in consolidation, is primarily due to new clients.

Salaries, wages and benefits expense for Conifer increased $46 million, or 23.8%, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015 due to an increase in employee headcount as a result of the growth in Conifer’s business primarily attributable to new clients.

Other operating expenses for Conifer increased $16 million, or 23.9%, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015 due to the growth in Conifer’s business primarily attributable to new clients.

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration, registration, verification of eligibility and benefits, liability identification and collection at point-of-service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

Consolidated

Impairment and Restructuring Charges, and Acquisition-Related Costs

During the three months ended March 31, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $28 million, consisting of approximately $2 million to write-down other intangible assets, $10 million of employee severance costs, $1 million of restructuring costs, $1 million of contract and lease termination fees, and $14 million in acquisition-related costs, which include $5 million of transaction costs and $9 million of acquisition integration costs.

During the three months ended March 31, 2015, we recorded impairment and restructuring charges and acquisition-related costs of $29 million, consisting of $6 million of employee severance costs, $3 million of restructuring costs and $20 million in acquisition-related costs, which include $7 million of transaction costs and $13 million in acquisition integration costs.

Litigation and Investigation Costs

Litigation and investigation costs for the three months ended March 31, 2016 and 2015 were $173 million and $3 million, respectively, and were primarily attributable to significant legal proceedings and governmental reviews described in Note 10 to our Condensed Consolidated Financial Statements.

Gains on Sales, Consolidation and Deconsolidation of Facilities

During the three months ended March 31, 2016, we recorded gains on sales, consolidation and deconsolidation of facilities of approximately $147 million, primarily comprised of a $113 million gain from the sale of our Atlanta-area facilities and $29 million of gains related to the consolidation and deconsolidation of certain businesses of our USPI joint venture due to ownership changes.

Interest Expense

Interest expense for the three months ended March 31, 2016 was $243 million compared to $199 million for the same period in 2015, primarily due to increased borrowings related to our recent acquisitions.

45

Income Tax Expense

During the three months ended March 31, 2016, we recorded income tax expense of $67 million in continuing operations on pre-tax earnings of $105 million. The recorded income tax differs from taxes calculated at the statutory rate primarily due to state income tax expense of approximately $13 million, tax benefits of $21 million related to net income attributable to noncontrolling partnership interests, which is excluded from the computation of the provision for income taxes, tax expense of $29 million related to nondeductible goodwill, tax benefits of $17 million related to nontaxable gains and related changes in deferred taxes, and tax expense of $26 million related to nondeductible litigation, compared to income tax expense of $16 million during the three months ended March 31, 2015.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $93 million for the three months ended March 31, 2016 compared to $29 million for the three months ended March 31, 2015. Net income attributable to noncontrolling interests for the three months ended March 31, 2016 was comprised of $6 million related to our Hospital Operations and other segment, $75 million related to our Ambulatory Care segment and $12 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $29 million was related to the minority interest in our USPI joint venture, which included $18 million attributable to $29 million of gains on the consolidation of certain businesses by our USPI joint venture and an associated $7 million favorable income tax adjustment. The portion related to our Conifer segment is due to Catholic Health Initiatives’ 23.8% ownership interest in our Conifer Health Solutions, LLC subsidiary.

ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, from time to time we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non-GAAP measure that we use in our analysis of the performance of our business, which we define as net income (loss) attributable to our common shareholders before: (1) the cumulative effect of changes in accounting principle, net of tax; (2) net loss (income) attributable to noncontrolling interests; (3) preferred stock dividends; (4) income (loss) from discontinued operations, net of tax; (5) income tax benefit (expense); (6) investment earnings (loss); (7) gain (loss) from early extinguishment of debt; (8) net gain (loss) on sales of investments; (9) interest expense; (10) litigation and investigation benefit (costs), net of insurance recoveries; (11) hurricane insurance recoveries, net of costs; (12) net gains (losses) on sales, consolidation and deconsolidation of facilities; (13) impairment and restructuring charges and acquisition-related costs; and (14) depreciation and amortization. As is the case with all non-GAAP measures, investors should consider the limitations associated with this metric, including the potential lack of comparability of this measure from one company to another, and should recognize that Adjusted EBITDA does not provide a complete measure of our operating performance because it excludes many items that are included in our financial statements. Accordingly, investors are encouraged to use GAAP measures when evaluating our financial performance.

46

The table below shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to our common shareholders (the most comparable GAAP term) for the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016			2015
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$	(59)		$	47
Less: Net income attributable to noncontrolling interests		(93)			(29)
Net income (loss) from discontinued operations, net of tax		(4)			1
Income from continuing operations		38			75
Income tax expense		(67)			(16)
Investment earnings		1			—
Interest expense		(243)			(199)
Operating income		347			290
Litigation and investigation costs		(173)			(3)
Gains on sales, consolidation and deconsolidation of facilities		147			—
Impairment and restructuring charges, and acquisition-related costs		(28)			(29)
Depreciation and amortization		(212)			(207)
Adjusted EBITDA	$	613		$	529
Net operating revenues	$	5,044		$	4,424
Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)		12.2	%		12.0	%

LIQUIDITY AND CAPITAL RESOURCES

CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under contracts and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report.

As part of our long-term objective to manage our capital structure, we may from time to time seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities subject to prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. These actions are part of our strategy to manage our leverage and capital structure over time, which is dependent on our total amount of debt, our available cash balances and our operating results.

At March 31, 2016, using the last 12 months of Adjusted EBITDA, including our USPI joint venture and Aspen’s last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 5.68x on a consolidated basis. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including acquisitions that involve the assumption of long-term debt. We intend to manage this ratio by following our business plan, managing our cost structure, possible asset divestitures and through other changes in our capital structure, including, if appropriate, the issuance of equity or convertible securities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements (including those required to achieve compliance with the HIT requirements under ARRA), introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with the acquisitions of businesses. Capital expenditures were $208 million and $184 million in the three months ended March 31, 2016 and 2015, respectively. We anticipate that our

47

capital expenditures for continuing operations for the year ending December 31, 2016 will total approximately $850 million to $900 million, including $133 million that was accrued as a liability at December 31, 2015. Our budgeted 2016 capital expenditures include approximately $5 million to improve disability access at certain of our facilities pursuant to the terms of a negotiated consent decree.

During the three months ended March 31, 2016,  we completed the sale of our Atlanta-area hospitals – Atlanta Medical Center and its South Campus, North Fulton Hospital, Spalding Regional Hospital and Sylvan Grove Hospital – as well as 26 physician clinics.  As a result of this transaction, we recorded a pre-tax gain on sale of approximately $113 million in the three months ended March 31, 2016.

Interest payments, net of capitalized interest, were $132 million and $117 million in the three months ended March 31, 2016 and 2015, respectively.

Income tax payments, net of tax refunds, were approximately $6 million in the three months ended March 31, 2016, and income tax refunds, net of tax payments, were approximately $1 million in the three months ended March 31, 2015.

SOURCES AND USES OF CASH

Our liquidity for the three months ended March 31, 2016 was primarily derived from net cash provided by operating activities, cash on hand and borrowings under our revolving credit facility. We had approximately $728 million of cash and cash equivalents on hand at March 31, 2016 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $996 million based on our borrowing base calculation at March 31, 2016.

Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections and levels of bad debt due to shifts in payer mix and other factors.

Net cash provided by operating activities was $147 million in the three months ended March 31, 2016 compared to $57 million net cash used in operating activities in the three months ended March 31, 2015. Key positive and negative factors contributing to the change between the 2016 and 2015 periods include the following:

· Increased income from continuing operations before income taxes of $84 million, excluding net gain on sales of investments, investment earnings (loss), gain (loss) from early extinguishment of debt, interest expense, gains on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, and depreciation and amortization in the three months ended March 31, 2016 compared to the three months ended March 31, 2015;

· $44 million less cash used by the change in accounts receivable, net of provision for doubtful accounts, in the 2016 period;

· Approximately $132 million of additional net cash proceeds in the 2016 period related to supplemental Medicaid programs, primarily in California and Texas;

· Higher aggregate annual 401(k) matching contributions and annual incentive compensation payments of $18 million and $9 million, respectively, in the three months ended March 31, 2016 compared to the three months ended March 31, 2015;

· An increase of $36 million in payments on reserves for restructuring charges, acquisition-related costs, and litigation costs and settlements; and

· Higher interest payments of $15 million.

48

We continue to seek further initiatives to increase the efficiency of our balance sheet by generating incremental cash, including by means of the sale of underutilized or inefficient assets.

Capital expenditures were $208 million and $184 million in the three months ended March 31, 2016 and 2015, respectively.

We record our investments that are available-for-sale at fair market value. As shown in Note 14 to our Condensed Consolidated Financial Statements, the majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

Credit Agreement. On December 4, 2015, we entered into an amendment to our existing senior secured revolving credit facility (as amended, “Credit Agreement”) in order to, among other things, extend the scheduled maturity date of the facility, reduce the rates of certain interest and fees payable under the facility and remove certain restrictions with respect to the borrowing base eligibility of certain account receivable. The Credit Agreement provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. The Credit Agreement has a scheduled maturity date of December 4, 2020. We are in compliance with all covenants and conditions in our Credit Agreement. At March 31, 2016, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $4 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $996 million was available for borrowing under the Credit Agreement at March 31, 2016.

Letter of Credit Facility. We have a letter of credit facility agreement (“LC Facility”) that provides for the issuance of standby and documentary letters of credit (including certain letters of credit originally issued under our prior credit agreement, which we transferred to the LC Facility), from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The LC Facility has a scheduled maturity date of March 7, 2017. We are in compliance with all covenants and conditions in our LC Facility. At March 31, 2016, we had approximately $139 million of standby letters of credit outstanding under the LC Facility.

For information regarding our long-term debt and capital lease obligations, see Note 5 to our Condensed Consolidated Financial Statements.

LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide significant flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest and income tax payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that has caused, and in the future could cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, availability under our Credit Agreement, anticipated future cash provided by operating activities, and our investments in marketable securities of our captive insurance companies classified as noncurrent investments on our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings or potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of

49

businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we acquire. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate cash from operations, as well as by the various risks and uncertainties discussed in this and other sections of this report, including any costs associated with a significant monetary resolution of the Clinica de la Mama qui tam action and criminal investigation described in Note 10 to our Condensed Consolidated Financial Statements.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our period-end balance sheets. In addition, we do not have significant exposure to floating interest rates given that substantially all of our current long-term indebtedness has fixed rates of interest.

We continue to aggressively identify and implement further actions to control costs and enhance our operating performance, including cash flow. Among the areas being addressed are capital allocation priorities, volume growth, including the acquisition of outpatient businesses, physician recruitment and alignment strategies, expansion of our Conifer services businesses, managed care payer contracting, procurement efficiencies, cost standardization, bad debt expense reduction initiatives, underperforming hospitals and portfolio optimization, and certain hospital and overhead costs not related to patient care. Although these initiatives may result in improved performance, our performance may remain somewhat below our hospital management company peers because of geographic and other differences in hospital portfolios.

OFF-BALANCE SHEET ARRANGEMENTS

Our consolidated operating results for the three months ended March 31, 2016 and 2015 include $2 million and $20 million, respectively, of net operating revenues and less than $1 million and $1 million, respectively, of operating income generated from hospitals operated by us under operating lease arrangements (one hospital in the three months ended March 31, 2016, which was sold effective March 31, 2016, and two hospitals in the three months ended March 31, 2015). In accordance with GAAP, the applicable buildings and the future lease obligations under these arrangements are not recorded on our consolidated balance sheet.

We have no other off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $232 million of standby letters of credit outstanding and guarantees at March 31, 2016.

CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates have not changed from the description provided in our Annual Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The table below presents information about certain of our market-sensitive financial instruments at March 31, 2016. The fair values were determined based on quoted market prices for the same or similar instruments. The

50

average effective interest rates presented are based on the rate in effect at the reporting date. The effects of unamortized premiums and discounts are excluded from the table.

	Maturity Date, Years Ending December 31,
	2016			2017			2018			2019			2020			Thereafter			Total			Fair Value
	(Dollars in Millions)
Fixed rate long-term debt	$	132		$	159		$	1,136		$	1,679		$	3,411		$	7,357		$	13,874		$	13,701
Average effective interest rates		5.1	%		6.6	%		6.5	%		5.5	%		6.7	%		7.1	%		6.7	%
Variable rate long-term debt	$	—		$	—		$	—		$	—		$	900		$	—		$	900		$	933
Average effective interest rates		—			—			—			—			4.1	%		—	%		—	%

At March 31, 2016, the potential reduction of annual pretax earnings due to a one percentage point (100 basis point) increase in variable interest rates on long-term debt would be approximately $9 million.

At March 31, 2016, we had long-term, market-sensitive investments held by our captive insurance subsidiaries. Our market risk associated with our investments in debt securities classified as non-current assets is substantially mitigated by the long-term nature and type of the investments in the portfolio.

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. Thus, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report with respect to our operations that existed prior to the USPI joint venture and Aspen transactions. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

51

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material pending legal proceedings in which we are involved, see Note 10 to our Condensed Consolidated Financial Statements, which is incorporated by reference.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.

ITEM 6. EXHIBITS

The following exhibits are filed with this report:

(10)	Letter from the Registrant to J. Eric Evans, dated March 22, 2016*
(31)	Rule 13a-14(a)/15d-14(a) Certifications
	(a)	Certification of Trevor Fetter, Chief Executive Officer and Chairman of the Board of Directors
	(b)	Certification of Daniel J. Cancelmi, Chief Financial Officer
(32)	Section 1350 Certification of Trevor Fetter, Chief Executive Officer and Chairman of the Board of Directors, and Daniel J. Cancelmi, Chief Financial Officer
(101 INS)	XBRL Instance Document
(101 SCH)	XBRL Taxonomy Extension Schema Document
(101 CAL)	XBRL Taxonomy Extension Calculation Linkbase Document
(101 DEF)	XBRL Taxonomy Extension Definition Linkbase Document
(101 LAB)	XBRL Taxonomy Extension Label Linkbase Document
(101 PRE)	XBRL Taxonomy Extension Presentation Linkbase Document

*  Management contract or compensatory plan or arrangement

52

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		TENET HEALTHCARE CORPORATION
		(Registrant)
Date: May 2, 2016	By:	/s/ R. SCOTT RAMSEY
		R. Scott Ramsey
		Vice President and Controller
		(Principal Accounting Officer)

53

EX-10

Exhibit 10

[Letterhead of Tenet Healthcare Corporation]

March 22, 2016

Jason Eric Evans

[Address Line 1]

[Address Line 2]

Dear Eric:

It has been a pleasure for both me and others here at Tenet to work with you and see your extensive accomplishments since you joined us in 2004.  I believe that you would be an outstanding addition to our Executive Leadership Team.  I am pleased to offer you the position of President of Hospital Operations at Tenet Healthcare (as an employee of Tenet Employment, Inc.) effective March 22, 2016.  This position will report to me and will be located at our headquarters in Dallas, TX. 

Compensation and Benefits: 

a. Base Compensation:  Your base compensation will be an annual exempt rate of $650,000, payable bi-weekly.

b. Health & Welfare Benefits:  You will continue to receive all standard health and welfare benefits in accordance with Tenet plans.

c. Annual Incentive Plan:   Your target award will be 100% of your base salary, and the actual result is based on our performance vs. targets using the metrics of Tenet’s hospital balanced score card.  Actual payouts from the AIP plan can vary from 0% to 200% of target.

d. Manager’s Time-Off Plan:  You will receive four weeks of paid time off and 9 paid holidays during the year under the company’s paid time off plan (MTO). In addition, we offer 4 additional discretionary holidays during the winter break before the New Year.

e. Deferred Compensation Plan:  The Deferred Compensation Plan (DCP) provides pre-tax compensation deferral options, some of which are eligible for a company match. 

f. Long-Term Incentive Award:  You will receive a one-time initial grant of restricted stock units valued at $1,000,000 on the last business day of the month you assume the role.  Half of this award will vest ratably on each of the first three anniversaries of the grant date.  The remaining half of the award will vest on the third anniversary of the grant date based on a three year performance on financial metrics.

Jason Eric Evans

March 22, 2016

Page 2 of 3

g. Executive Severance Plan:  The Tenet Executive Severance Plan (ESP) will provide you with the following benefits:

· Two and one-half years of base salary and target annual bonus for a Qualifying Termination as defined in the ESP.

· Three years of base salary and target annual bonus for Qualifying Termination related to a Change of Control

h. Executive Retirement Account (ERA):  You will receive an annual credit equal to twenty percent (20%) of your base salary while you are employed in a position that is eligible for benefits under the plan.  The credit will occur annually on July 1. 

Terms and Conditions of Employment:  This offer is contingent upon the execution of the enclosed Confidentiality, Non-Compete and Non-Interference Agreement.  Your employment with Tenet will be on an at-will basis, which means that either you or the company may terminate the employment relationship, with or without notice and with or without cause at any time.  As used in this letter, the term "cause" shall include, but shall not be limited to, dishonesty, fraud, willful misconduct, self-dealing or violations of the Tenet Standards of Conduct, breach of fiduciary duty (whether or not involving personal profit), failure, neglect or refusal to perform your duties in any material respect, violation of law (except traffic violations or similar minor infractions), violation of Tenet's Human Resources or other Policies, or any material breach of this letter.

Compliance with Tenet Policies, Rules and Regulations:  By signing this letter below, you agree to abide by all Tenet Human Resources and other policies, procedures, rules and regulations currently in effect or that may be adopted from time to time, including the Tenet Performance Management policy and the Tenet Standards of Conduct.  To the extent that any such policies, rules or regulations, or any benefit plans in which you are a participant, conflict with the terms of this letter, the actual terms of those policies or plans shall control.

Ethics & Compliance:  All Tenet employees are required to attend Ethics & Compliance classes within established Tenet policy guidelines, as well as a refresher course every year.  Please contact Paul Slavin, or access the company intranet site at www.eTenet.com, for additional information.

Standards of Conduct:  As an employee of Tenet, you agree to abide by Tenet’s Standards of Conduct, which reflect Tenet’s basic values of high-quality, cost-effective health services; honesty, trustworthiness, and reliability in all relationships; leadership in the development of partnership arrangements with providers of health services; good corporate citizenship in the communities where Tenet provides services; pursuit of fiscal responsibility and growth; compliance with all applicable rules, regulations, policies and procedures; and fair treatment of employees.

Conflict Resolution:  As a condition of employment, you agree to abide by Tenet's Fair Treatment Process which includes final and binding Arbitration as a resolution to any grievance that results out of your employment or termination of employment with Tenet.

Jason Eric Evans

March 22, 2016

Page 3 of 3

Eric, I would be delighted to have you as part of the team. If you accept this offer, please sign and return the letter to Paul Slavin by March 29, 2016.  Please feel free to reach out to me directly or to contact Paul if you have any additional questions.

Sincerely,

/s/ Trevor Fetter

Trevor Fetter

Chairman and CEO

cc:Paul Slavin, VP, Compensation, Benefits & Corporate HR

Acknowledged and accepted:

/s/ J. Eric Evans	Date:	March 24, 2016
Signature

EX-31.(A)

Exhibit 31(a)

Rule 13a-14(a)/15d-14(a) Certification

I, Trevor Fetter, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: May 2, 2016

/s/ TREVOR FETTER

Trevor Fetter

Chief Executive Officer and Chairman of the Board of Directors

EX-31.(B)

Exhibit 31(b)

Rule 13a-14(a)/15d-14(a) Certification

I, Daniel J. Cancelmi, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: May 2, 2016

/s/ DANIEL J. CANCELMI

Daniel J. Cancelmi

Chief Financial Officer

EX-32

Exhibit 32

Certifications Pursuant to Section 1350 of Chapter 63
of Title 18 of the United States Code

We, the undersigned Trevor Fetter and Daniel J. Cancelmi, being, respectively, the Chairman, President and Chief Executive Officer and the Chief Financial Officer of Tenet Healthcare Corporation (the “Registrant”), do each hereby certify that (i) the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (the “Form 10-Q”), to be filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant and its subsidiaries.

Date: May 2, 2016	/s/ TREVOR FETTER
	Trevor Fetter
	Chief Executive Officer and Chairman of the Board of Directors
Date: May 2, 2016	/s/ DANIEL J. CANCELMI
	Daniel J. Cancelmi
	Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. §1350; it is not being filed for purposes of Section 18 of the Securities Exchange Act, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 27, 2016
Document and Entity Information
Entity Registrant Name	TENET HEALTHCARE CORP
Entity Central Index Key	0000070318
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		99,304,410
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 728	$ 356
Accounts receivable, less allowance for doubtful accounts ($901 at March 31, 2016 and $887 at December 31, 2015)	2,807	2,704
Inventories of supplies, at cost	312	309
Income tax receivable		7
Assets held for sale	2	550
Other current assets	1,280	1,245
Total current assets	5,129	5,171
Investments and other assets	1,142	1,175
Deferred income taxes	726	776
Property and equipment, at cost, less accumulated depreciation and amortization ($4,538 at March 31, 2016 and $4,323 at December 31, 2015)	7,961	7,915
Goodwill	7,122	6,970
Other intangible assets, at cost, less accumulated amortization ($701 at March 31, 2016 and $659 at December 31, 2015)	1,686	1,675
Total assets	23,766	23,682
Current liabilities:
Current portion of long-term debt	172	127
Accounts payable	1,228	1,380
Accrued compensation and benefits	772	880
Professional and general liability reserves	161	177
Accrued interest payable	307	205
Liabilities held for sale		101
Accrued legal settlement costs	423	294
Other current liabilities	1,205	1,144
Total current liabilities	4,268	4,308
Long-term debt, net of current portion	14,350	14,383
Professional and general liability reserves	623	578
Defined benefit plan obligations	593	595
Other long-term liabilities	625	594
Total liabilities	$ 20,459	$ 20,458
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries	$ 2,381	$ 2,266
Shareholders' equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 147,692,493 shares issued at March 31, 2016 and 146,920,454 shares issued at December 31, 2015	7	7
Additional paid-in capital	4,804	4,815
Accumulated other comprehensive loss	(160)	(164)
Accumulated deficit	(1,609)	(1,550)
Common stock in treasury, at cost, 48,424,273 shares at March 31, 2016 and 48,425,298 shares at December 31, 2015	(2,417)	(2,417)
Total shareholders' equity	625	691
Noncontrolling interests	301	267
Total equity	926	958
Total liabilities and equity	$ 23,766	$ 23,682

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
CONDENSED CONSOLIDATED BALANCE SHEETS
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 901	$ 887
Property and equipment, accumulated depreciation and amortization (in dollars)	4,538	4,323
Other intangible assets, accumulated amortization (in dollars)	$ 701	$ 659
Common stock, par value (in dollars per share)	$ 0.05	$ 0.05
Common stock, authorized shares	262,500,000	262,500,000
Common stock, shares issued	147,692,493	146,920,454
Common stock in treasury, shares	48,424,273	48,425,298

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net operating revenues:
Net operating revenues before provision for doubtful accounts	$ 5,420	$ 4,787
Less: Provision for doubtful accounts	376	363
Net operating revenues	5,044	4,424
Equity in earnings of unconsolidated affiliates	24	4
Operating expenses:
Salaries, wages and benefits	2,402	2,125
Supplies	811	687
Other operating expenses, net	1,242	1,093
Electronic health record incentives		(6)
Depreciation and amortization	212	207
Impairment and restructuring charges, and acquisition-related costs	28	29
Litigation and investigation costs	173	3
Gains on sales, consolidation and deconsolidation of facilities	(147)
Operating income	347	290
Interest expense	(243)	(199)
Investment earnings	1
Net income from continuing operations, before income taxes	105	91
Income tax benefit (expense)	(67)	(16)
Net income from continuing operations, before discontinued operations	38	75
Discontinued operations:
Loss from operations	(5)	(1)
Litigation and investigation costs		3
Income tax benefit (expense)	1	(1)
Net income (loss) from discontinued operations	(4)	1
Net income	34	76
Less: Net income attributable to noncontrolling interests	93	29
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	(59)	47
Amounts available (attributable) to Tenet Healthcare Corporation common shareholders
Net income from continuing operations, net of tax	(55)	46
Net income (loss) from discontinued operations, net of tax	(4)	1
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$ (59)	$ 47
Basic
Continuing operations (in dollars per share)	$ (0.56)	$ 0.47
Discontinued operations (in dollars per share)	(0.04)	0.01
Total loss per share, Basic (in dollars per share)	(0.60)	0.48
Diluted
Continuing operations (in dollars per share)	(0.56)	0.46
Discontinued operations (in dollars per share)	(0.04)	0.01
Total loss per share, Diluted (in dollars per share)	$ (0.60)	$ 0.47
Weighted average shares and dilutive securities outstanding (in thousands):
Basic (in shares)	98,768	98,699
Diluted (in shares)	98,768	100,872

XML

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME
Net income	$ 34	$ 76
Other comprehensive income:
Amortization of net actuarial loss included in net periodic benefit costs		3
Unrealized gains on securities held as available-for-sale	3	1
Foreign currency translation adjustments	2
Other comprehensive income before income taxes	5	4
Income tax expense related to items of other comprehensive income	(1)	(1)
Total other comprehensive income, net of tax	4	3
Comprehensive net income	38	79
Less: Comprehensive income attributable to noncontrolling interests	93	29
Comprehensive net income available (loss attributable) to Tenet Healthcare Corporation common shareholders	$ (55)	$ 50

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Net income	$ 34	$ 76
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	212	207
Provision for doubtful accounts	376	363
Deferred income tax expense	31	12
Stock-based compensation expense	16	15
Impairment and restructuring charges, and acquisition-related costs	28	29
Litigation and investigation costs	173	3
Gains on sales, consolidation and deconsolidation of facilities	(147)
Equity in earnings of unconsolidated affiliates, net of distributions received	12	(4)
Amortization of debt discount and debt issuance costs	10	7
Pre-tax loss (income) from discontinued operations	5	(2)
Other items, net	2	(4)
Changes in cash from operating assets and liabilities:
Accounts receivable	(453)	(484)
Inventories and other current assets	(18)	(74)
Income taxes	28	8
Accounts payable, accrued expenses and other current liabilities	(114)	(200)
Other long-term liabilities	24	28
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(69)	(33)
Net cash used in operating activities from discontinued operations, excluding income taxes	(3)	(4)
Net cash provided by (used in) operating activities	147	(57)
Cash flows from investing activities:
Purchases of property and equipment - continuing operations	(208)	(184)
Purchases of businesses or joint venture interests, net of cash acquired	(29)	(11)
Proceeds from sales of facilities and other assets	573
Proceeds from sales of marketable securities, long-term investments and other assets	12	6
Purchases of equity investments	(18)
Other long-term assets	(10)	2
Net cash provided by (used in) investing activities	320	(187)
Cash flows from financing activities:
Repayments of borrowings under credit facility	(995)	(690)
Proceeds from borrowings under credit facility	995	820
Repayments of other borrowings	(38)	(32)
Proceeds from other borrowings	1	401
Debt issuance costs		(4)
Distributions paid to noncontrolling interests	(44)	(11)
Contributions from noncontrolling interests		2
Purchase of noncontrolling interest		(254)
Proceeds from exercise of stock options		7
Other items, net	(14)	(3)
Net cash provided by (used in) financing activities	(95)	236
Net increase (decrease) in cash and cash equivalents	372	(8)
Cash and cash equivalents at beginning of period	356	193
Cash and cash equivalents at end of period	728	185
Supplemental disclosures:
Interest paid, net of capitalized interest	(132)	(117)
Income tax payments, net	$ (6)	$ 1

XML

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2016

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE 1. BASIS OF PRESENTATION

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At March 31, 2016, we operated 84 hospitals, 20 short-stay surgical hospitals, over 475outpatient centers, nine facilities in the United Kingdom and six health plans through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). The results of 142 of these facilities, in which we hold noncontrolling interests, are recorded using the equity method of accounting. Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2015 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  Certain prior-year amounts have been reclassified to conform to the current-year presentation.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three month period ended March 31, 2016are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the number of covered lives managed by our health plans and the plans’ ability to effectively manage medical costs; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Translation of Foreign Currencies

The accounts of European Surgical Partners, Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs.

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended
	March 31,
	2016		2015
General Hospitals:
Medicare	$	859	$	898
Medicaid		373		385
Managed care		2,626		2,405
Indemnity, self-pay and other		437		414
Acute care hospitals — other revenue		7		15
Other:
Other operations		1,118		670
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $728 million and $356 million at March 31, 2016 and December 31, 2015, respectively. At March 31, 2016 and December 31, 2015, our book overdrafts were approximately $256 million and $301 million, respectively, which were classified as accounts payable.

At March 31, 2016 and December 31, 2015, approximately $175 million and $171 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries and our health plans.

Also at March 31, 2016 and December 31, 2015, we had $110 million and $133 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $63 million and $95 million, respectively, were included in accounts payable.

During the three months ended March 31, 2016 and 2015, we entered into non-cancellable capital leases of approximately $31 million and $33 million, respectively, primarily for buildings and equipment.

Other Intangible Assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at March 31, 2016 and December 31, 2015:

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At March 31, 2016:
Capitalized software costs	$	1,495	$	(625)	$	870
Trade names		106		—		106
Contracts		669		(30)		639
Other		117		(46)		71
Total	$	2,387	$	(701)	$	1,686

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At December 31, 2015:
Capitalized software costs	$	1,456	$	(594)	$	862
Trade names		106		—		106
Contracts		653		(26)		627
Other		119		(39)		80
Total	$	2,334	$	(659)	$	1,675

Estimated future amortization of intangibles with finite useful lives at March 31, 2016 is as follows:

			Years Ending December 31,										Later
	Total		2016		2017		2018		2019		2020		Years
Amortization of intangible assets	$	1,207	$	141	$	174	$	146	$	122	$	89	$	535

Investments in Unconsolidated Affiliates

We control 213 of the facilities operated by our Ambulatory Care segment and, therefore, consolidate their results (211 are consolidated within our Ambulatory Care segment and two are consolidated within our Hospital Operations and other segment). We account for many of the facilities our Ambulatory Care segment operates (122 of 335 at March 31, 2016) and four of the hospitals our Hospital Operations and other segment operates under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. Summarized financial information for these equity method investees is included in the following table.

	Three Months Ended
	March 31, 2016
Net operating revenues	$	578
Net income	$	105
Net income attributable to the investees	$	69

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

3 Months Ended

Mar. 31, 2016

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

NOTE 2. ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The principal components of accounts receivable are shown in the table below:

	March 31,		December 31,
	2016		2015
Continuing operations:
Patient accounts receivable	$	3,606	$	3,486
Allowance for doubtful accounts		(901)		(887)
Estimated future recoveries from accounts assigned to our Conifer subsidiary		146		144
Net cost reports and settlements payable and valuation allowances		(47)		(42)
		2,804		2,701
Discontinued operations		3		3
Accounts receivable, net	$	2,807	$	2,704

At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts was 25.0% and 25.4%, respectively, of our patient accounts receivable. Accounts that are pursued for collection through Conifer’s regional business offices are maintained on our hospitals’ books and reflected in patient accounts receivable with an allowance for doubtful accounts established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimate this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors. At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts for self-pay was 81.2% and 80.6%, respectively, of our self-pay patient accounts receivable, including co-pays and deductibles owed by patients with insurance. At March 31, 2016 and December 31, 2015, our allowance for doubtful accounts for managed care was 8.4% and 7.5%, respectively, of our managed care patient accounts receivable.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. The table below shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our self-pay patients and charity care patients, and revenues attributable to Medicaid DSH and other supplemental revenues we recognized in three months ended March 31, 2016 and 2015.

	Three Months Ended
	March 31,
	2016		2015
Estimated costs for:
Self-pay patients	$	165	$	164
Charity care patients	$	44	$	36
Medicaid DSH and other supplemental revenues	$	227	$	247

At March 31, 2016 and December 31, 2015, we had approximately $450 million and $387 million, respectively, of receivables recorded in other current assets and approximately $174 million and $139 million, respectively, of payables recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program.

XML

ASSETS AND LIABILITIES HELD FOR SALE

3 Months Ended

Mar. 31, 2016

ASSETS AND LIABILITIES HELD FOR SALE

ASSETS AND LIABILITIES HELD FOR SALE

NOTE 3. ASSETS AND LIABILITIES HELD FOR SALE

Our hospitals, physician practices and related assets in Georgia met the criteria to be classified as assets held for sale in the three months ended June 30, 2015. In accordance with the guidance in the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 360, “Property, Plant and Equipment,” we classified $549 million of our assets in Georgia as “assets held for sale” in current assets and $101 million of our liabilities in Georgia as “liabilities held for sale” in current liabilities in the accompanying Condensed Consolidated Balance Sheet at December 31, 2015. We completed the sale of our Georgia assets on March 31, 2016 at a transaction price of approximately $575 million and recognized a gain on sale of approximately $113 million. Because we did not sell the related accounts receivable related to the pre-closing period, net receivables of approximately $141 million are included in accounts receivable, less allowance for doubtful accounts in the accompanying Condensed Consolidated Balance Sheet at March 31, 2016.

XML

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

3 Months Ended

Mar. 31, 2016

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

During the three months ended March 31, 2016, we recorded impairment and restructuring charges and acquisition-related costs of $28 million primarily related to our Hospital Operations and other segment, consisting of approximately $2 million to write-down other intangible assets, $10 million of employee severance costs, $1 million of restructuring costs, $1 million of contract and lease termination fees, and $14 million in acquisition-related costs, which include $5 million of transaction costs and $9 million of acquisition integration charges.

During the three months ended March 31, 2015, we recorded impairment and restructuring charges and acquisition-related costs of $29 million, consisting of $6 million of employee severance costs, $3 million of restructuring costs, and $20 million in acquisition-related costs, which include $7 million of transaction costs and $13 million of acquisition integration charges.

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve the facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

At March 31, 2016, our continuing operations consisted of three reportable segments, Hospital Operations and other, Ambulatory Care and Conifer.Within our Hospital Operations and other segment, our regions and markets are reporting units used to perform our goodwill impairment analysis and are one level below our reportable business segment level. Our Ambulatory Care segment consists of the operations of our USPI joint venture and our Aspen facilities.

Our Hospital Operations and other segment was structured as follows at March 31, 2016:

· Our Florida region included all of our hospitals and other operations in Florida;

· Our Northeast region included all of our hospitals and other operations in Illinois, Massachusetts and Pennsylvania;

· Our Southern region included all of our hospitals and other operations in Alabama, Georgia, South Carolina and Tennessee;

· Our Texas region included all of our hospitals and other operations in Missouri, New Mexico and Texas;

· Our Western region included all of our hospitals and other operations in Arizona and California; and

· Our Detroit market included all of our hospitals and other operations in the Detroit, Michigan area.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS

3 Months Ended

Mar. 31, 2016

LONG-TERM DEBT AND LEASE OBLIGATIONS

LONG-TERM DEBT AND LEASE OBLIGATIONS

NOTE 5. LONG-TERM DEBT AND LEASE OBLIGATIONS

The table below shows our long-term debt at March 31, 2016 and December 31, 2015:

	March 31,		December 31,
	2016		2015
Senior notes:
5%, due 2019	$	1,100	$	1,100
51/2%, due 2019		500		500
63/4%, due 2020		300		300
8%, due 2020		750		750
81/8%, due 2022		2,800		2,800
63/4%, due 2023		1,900		1,900
67/8%, due 2031		430		430
Senior secured notes:
61/4%, due 2018		1,041		1,041
43/4%, due 2020		500		500
6%, due 2020		1,800		1,800
Floating % due 2020		900		900
41/2%, due 2021		850		850
43/8%, due 2021		1,050		1,050
Capital leases and mortgage notes		853		852
Unamortized issue costs, note discounts and premium		(252)		(263)
Total long-term debt		14,522		14,510
Less current portion		172		127
Long-term debt, net of current portion	$	14,350	$	14,383

Credit Agreement

On December 4, 2015, we entered into an amendment to our existing senior secured revolving credit facility (as amended, “Credit Agreement”) in order to, among other things, extend the scheduled maturity date of the facility, reduce the rates of certain interest and fees payable under the facility, and remove certain restrictions with respect to the borrowing base eligibility of certain accounts receivable. The Credit Agreement provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. The Credit Agreement, which has a scheduled maturity date of December 4, 2020, is collateralized by patient accounts receivable of substantially all of our domestic wholly owned hospitals. In addition, borrowings under the Credit Agreement are guaranteed by substantially all of our wholly owned domestic hospital subsidiaries. Outstanding revolving loans accrue interest at a base rate plus a margin ranging from 0.25% to 0.75% per annum or the London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.25% to 1.75% per annum, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible accounts receivable, including self-pay accounts. At March 31, 2016, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $4 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $996 million was available for borrowing under the Credit Agreement at March 31, 2016.

Letter of Credit Facility

On March 7, 2014, we entered into a letter of credit facility agreement (“LC Facility”) that provides for the issuance of standby and documentary letters of credit (including certain letters of credit issued under our prior credit agreement, which we transferred to the LC Facility (the “Preexisting Letters of Credit”)), from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The LC Facility has a scheduled maturity date of March 7, 2017, and obligations thereunder are guaranteed by and secured by a first priority pledge of the capital stock and other ownership interests of certain of our domestic hospital subsidiaries on an equal ranking basis with our existing senior secured notes.

Drawings under any letter of credit issued under the LC Facility (including the Preexisting Letters of Credit) that we have not reimbursed within three business days after notice thereof will accrue interest at a base rate plus a margin equal to 0.875% per annum. An unused commitment fee is payable at an initial rate of 0.50% per annum with a step down to 0.375% per annum based on the secured debt to EBITDA ratio of 3.00 to 1.00. A per annum fee on the aggregate outstanding amount of issued but undrawn letters of credit (including the Preexisting Letters of Credit) will accrue at a rate of 1.875% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At March 31, 2016, we had approximately $139 million of standby letters of credit outstanding under the LC Facility.

XML

GUARANTEES

3 Months Ended

Mar. 31, 2016

GUARANTEES

GUARANTEES

NOTE 6. GUARANTEES

At March 31, 2016, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $89 million. We had a total liability of $75 million recorded for these guarantees included in other current liabilities at March 31, 2016.

At March 31, 2016, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $35 million. Of the total, $17 million relates to the obligations of consolidated subsidiaries, which obligations are recorded in the accompanying Condensed Consolidated Balance Sheet at March 31, 2016.

XML

EMPLOYEE BENEFIT PLANS

3 Months Ended

Mar. 31, 2016

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS

NOTE 7. EMPLOYEE BENEFIT PLANS

At March 31, 2016, approximately 1.7 million shares of common stock were available under our 2008 Stock Incentive Plan for future stock option grants and other incentive awards, including restricted stock units. Options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unit is a contractual right to receive one share of our common stock or the equivalent value in cash in the future. Options and time-based restricted stock units typically vestone-third on each of the first three anniversary dates of the grant; however, certain special retention awards may have longer vesting periods. In addition, we grant performance-based restricted stock units (and, in prior years, have granted performance-based options) that vest subject to the achievement of specified performance goals within a specified timeframe.

Our Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 include $14 million and $18 million, respectively, of pretax compensation costs related to our stock-based compensation arrangements recorded in salaries, wages and benefits.

Stock Options

The following table summarizes stock option activity during the three months ended March 31, 2016:

		Weighted Average
		Exercise Price		Aggregate		Weighted Average
	Options	Per Share		Intrinsic Value		Remaining Life
					(In Millions)
Outstanding at December 31, 2015	1,606,842	$	22.87
Granted	—		—
Exercised	(3,950)		4.56
Forfeited/Expired	(29,392)		4.56
Outstanding at March 31, 2016	1,573,500		22.75	$	13	2.9	years
Vested and expected to vest at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years
Exercisable at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years

There were3,950 stock options exercised during the three months ended March 31, 2016 with an aggregate intrinsic value of less than $1 million, and 77,658 stock options exercised during the same period in 2015 with a less than $1 million aggregate intrinsic value.

At March 31, 2016, there were no unrecognized compensation costs related to stock options. Also, there were no stock options granted in the three months ended March 31, 2016 or 2015.

The following table summarizes information about our outstanding stock options at March 31, 2016:

	Options Outstanding					Options Exercisable
		Weighted Average
	Number of	Remaining		Weighted Average		Number of	Weighted Average
Range of Exercise Prices	Options	Contractual Life		Exercise Price		Options	Exercise Price
$0.00 to $4.569	202,152	2.9	years	$	4.56	202,152	$	4.56
$4.57 to $25.089	910,897	3.6	years		20.99	910,897		20.99
$25.09 to $32.569	182,000	0.9	years		26.40	182,000		26.40
$32.57 to $42.529	278,451	1.8	years		39.31	278,451		39.31
	1,573,500	2.9	years	$	22.75	1,573,500	$	22.75

Restricted Stock Units

The following table summarizes restricted stock unit activity during the three months ended March 31, 2016:

	Restricted Stock	Weighted Average Grant
	Units	Date Fair Value Per Unit
Unvested at December 31, 2015	3,627,232	$	44.69
Granted	1,231,727		31.08
Vested	(1,223,015)		43.68
Forfeited	(23,639)		45.05
Unvested at March 31, 2016	3,612,305	$	40.38

In the three months ended March 31, 2016, we granted 474,052 restricted stock units subject to time-vesting, of which 458,379 will vest and be settled ratably over a three-year period from the grant date, and 15,673 will vest and be settled on the third anniversary of the grant date. In January 2016, following the appointment of two new members of our Board of Directors, we also made initial grants totaling 5,084restricted stock units to these directors, as well as prorated annual grants totaling 5,614 restricted stock units. Both the initial grants and the annual grants vested immediately, however the initial grants will not settle until the directors’ separation from the Board, while the annual grants settle on the third anniversary of the grant date. In addition, we granted 455,437 performance-based restricted stock units to certain of our senior officers; the vesting of these restricted stock units is contingent on our achievement of specified three-year performance goals for the years 2016 to 2018. Provided the goals are achieved, the performance-based restricted stock units will vest and settle on the third anniversary of the grant date. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 455,437 units granted, depending on our level of achievement with respect to the performance goals. Moreover, in the three months ended March 31, 2016, we granted 291,540 restricted stock units as a result of our level of achievement with respect to prior-year target performance goals.

At March 31, 2016, there were $117 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 2.3 years.

XML

EQUITY

3 Months Ended

Mar. 31, 2016

EQUITY

EQUITY

NOTE 8. EQUITY

Changes in Shareholders’ Equity

The following table shows the changes in consolidated equity during the three months ended March 31, 2016 and 2015 (dollars in millions, share amounts in thousands):

	Tenet Healthcare Corporation Shareholders’ Equity
						Accumulated
	Common Stock			Additional		Other
	Shares	Issued Par		Paid-in		Comprehensive		Accumulated		Treasury		Noncontrolling
	Outstanding	Amount		Capital		Loss		Deficit		Stock		Interests		Total Equity
Balances at December 31, 2015	98,495	$	7	$	4,815	$	(164)	$	(1,550)	$	(2,417)	$	267	$	958
Net income  (loss)	—		—		—		—		(59)		—		13		(46)
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		10		10
Other comprehensive income	—		—		—		4		—		—		—		4
Purchases (sales) of businesses and noncontrolling interests	—		—		(7)		—		—		—		21		14
Stock-based compensation expense, tax benefit and issuance of common stock	773		—		(4)		—		—		—		—		(4)
Balances at March 31, 2016	99,268	$	7	$	4,804	$	(160)	$	(1,609)	$	(2,417)	$	301	$	926
Balances at December 31, 2014	98,382	$	7	$	4,614	$	(182)	$	(1,410)	$	(2,378)	$	134	$	785
Net income	—		—		—		—		47		—		8		55
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		1		1
Other comprehensive income	—		—		—		3		—		—		—		3
Purchases (sales) of businesses and noncontrolling interests	—		—		129		—		—		—		—		129
Stock-based compensation expense and issuance of common stock	782		—		8		—		—		1		—		9
Balance at March 31, 2015	99,164	$	7	$	4,751	$	(179)	$	(1,363)	$	(2,377)	$	133	$	972

XML

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

3 Months Ended

Mar. 31, 2016

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

NOTE 9. PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

Property Insurance

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis.

Professional and General Liability Reserves

At March 31, 2016 and December 31, 2015, the aggregate current and long-term professional and general liability reserves in our accompanying Condensed Consolidated Balance Sheets were approximately $784 million and $755 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 1.54% at March 31, 2016 and 2.09% at December 31, 2015.

If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

Included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations is malpractice expense of $93 million and $89 million for the three months ended March 31, 2016 and 2015, respectively.

XML

CLAIMS AND LAWSUITS

3 Months Ended

Mar. 31, 2016

CLAIMS AND LAWSUITS

CLAIMS AND LAWSUITS

NOTE 10. CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. As a result, we commonly become involved in disputes, litigation and regulatory matters incidental to our operations, including governmental investigations, personal injury lawsuits, employment claims and other matters arising out of the normal conduct of our business.

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information.

Governmental Reviews and Lawsuits

Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. The following matters are pending.

· Clinica de la Mama Qui Tam Action and Criminal Investigation—As previously disclosed, we and four of our hospital subsidiaries are defendants in civil qui tam litigation (United States of America, ex rel. Ralph D. Williams v. Health Management Associates, Inc., et al.) that alleges that the contractual arrangements entered into by the hospital subsidiaries with Hispanic Medical Management, Inc. (“HMM”) violated the federal and state anti-kickback statutes and false claims acts. HMM owned and operated clinics that provided, among other things, prenatal care predominantly to uninsured patients. Beginning in 2000, the hospital subsidiaries contracted with HMM for translation, marketing, management and Medicaid eligibility determination services. Subsequently, the Georgia Attorney General’s Office and the U.S. Attorney’s Office intervened in the qui tam action. Effective March 31, 2016, we sold the operating assets of three of the four hospital subsidiaries; however, we retained any potential liabilities arising from the litigation or the U.S. Department of Justice (“DOJ”) investigation discussed below.

If the plaintiff in the pending civil litigation were to prevail, the potential sanctions could include up to three times the reimbursement of relevant government program payments received by the four hospital subsidiaries for uninsured HMM patients treated at the hospitals, the assessment of civil penalties and potential exclusion from participation in federal healthcare programs.

Also as previously disclosed, the DOJ has been conducting a criminal investigation of us, certain of our subsidiaries and former employees with respect to the contractual arrangements between HMM and the four hospitals. We are cooperating in the investigation and have responded, and continue to respond, to document and other requests pursuant to subpoenas issued to us and the four subsidiaries.

In January 2016, we commenced discussions with the DOJ and the State of Georgia regarding potential resolution of the qui tam action and criminal investigation. In the three months ended March 31, 2016, we increased the aggregate accrual for these matters from $238 million to $407 million to reflect the most recent  offer we made on April 25, 2016 to resolve the criminal investigation and civil litigation. The offer was not accepted, but the parties continue to engage in discussions to resolve these matters. There can be no assurance that ongoing discussions will lead to a resolution. The terms of a final resolution of these matters may require us to pay significant fines and penalties and give rise to other costs or adverse consequences that materially exceed the accrual we have established. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution, we cannot estimate the amount of potential loss or range of reasonably possible loss in excess of the amount accrued that we may face.

In addition to the payment of a monetary penalty, the final terms of any resolution of these matters could include: (i) the execution by the Company of a Corporate Integrity Agreement or a non-prosecution agreement, which may provide for the appointment of a corporate monitor and ongoing compliance audits; (ii) a deferred prosecution agreement by an intermediate subsidiary of the Company; and (iii) a commitment that one or more of the hospital subsidiaries subject to the investigation and proceedings enter into a guilty plea. The non-monetary terms of any resolution could expose us to increased operating costs, reputational harm, administrative burdens, and diminished profits and revenues.

If our efforts to negotiate a settlement ultimately are unsuccessful, and we or our subsidiaries are determined to have violated the federal anti-kickback statute, the sanctions could include fines, which could be significant, and mandatory exclusion from participation in federal healthcare programs.

To the extent that either the civil or criminal matter discussed above is determined adversely to our interests, such determination could have a material adverse effect on our business, financial condition, results of operations or cash flows. 

Antitrust Class Action Lawsuit Filed by Registered Nurses in San Antonio

In Maderazo, et al. v. VHS San Antonio Partners, L.P. d/b/a Baptist Health Systems, et al., filed in June 2006 in the U.S. District Court for the Western District of Texas, a purported class of registered nurses employed by three unaffiliated San Antonio-area hospital systems allege those hospital systems, including Baptist Health System, and other unidentified San Antonio regional hospitals violated Section §1 of the federal Sherman Act by conspiring to depress nurses’ compensation and exchanging compensation-related information among themselves in a manner that reduced competition and suppressed the wages paid to such nurses. The suit seeks unspecified damages (subject to trebling under federal law), interest, costs and attorneys’ fees. The case had been stayed since 2008; however, in July 2015, the court lifted the stay and re-opened discovery. Because these proceedings are at an early stage, it is impossible at this time to predict their outcome with any certainty; however, we believe that the ultimate resolution of this matter will not have a material effect on our business, financial condition or results of operations. We will continue to seek to defeat class certification and vigorously defend ourselves against the plaintiffs’ allegations.

Ordinary Course Matters

We are also subject to other claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.

The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the three months ended March 31, 2016 and 2015:

	Balances at		Litigation and				Balances at
	Beginning		Investigation		Cash		End of
	of Period		Costs		Payments		Period
Three Months Ended March 31, 2016
Continuing operations	$	299	$	173	$	(45)	$	427
Discontinued operations		—		—		—		—
	$	299	$	173	$	(45)	$	427
Three Months Ended March 31, 2015
Continuing operations	$	73	$	3	$	(15)	$	61
Discontinued operations		10		(3)		—		7
	$	83	$	—	$	(15)	$	68

For the three months ended March 31, 2016 and 2015, we recorded costs of $173 million and $3 million, respectively, in continuing operations in connection with significant legal proceedings and governmental reviews. During the three months ended March 31, 2015, we reduced a previously established reserve for a legal matter in discontinued operations by approximately $3 million based on updated claims information.

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

3 Months Ended

Mar. 31, 2016

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

NOTE 11. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016		2015
Balances at beginning of period	$	2,266	$	401
Net income		80		21
Distributions paid to noncontrolling interests		(34)		(1)
Contributions from noncontrolling interests		6		1
Purchases and sales of businesses and noncontrolling interests, net		63		(214)
Balances at end of period	$	2,381	$	208

XML

INCOME TAXES

3 Months Ended

Mar. 31, 2016

INCOME TAXES

INCOME TAXES

NOTE 12. INCOME TAXES

During the three months ended March 31, 2016, we recorded income tax expense of $67 million in continuing operations on pre-tax earnings of $105 million. The recorded income tax differs from taxes calculated at the statutory rate primarily due to state income tax expense of approximately $13 million, tax benefits of $21 million related to net income attributable to noncontrolling partnership interests, which is excluded from the computation of the provision for income taxes, tax expense of $29 million related to nondeductible goodwill, tax benefits of $17 million related to nontaxable gains and related changes in deferred taxes, and tax expense of $26 million related to nondeductible litigation.

During the three months ended March 31, 2016, we decreased our estimated liabilities for uncertain tax positions by $3 million, net of related deferred tax assets. The total amount of unrecognized tax benefits at March 31, 2016 was $37 million, of which $34 million, if recognized, would impact our effective tax rate and income tax expense (benefit) from continuing operations.

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accrued interest and penalties on unrecognized tax benefits at March 31, 2016 were $5 million, all of which related to continuing operations.

At March 31, 2016, approximately $6 million of unrecognized federal and state tax benefits, as well as reserves for interest and penalties, may decrease in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

XML

EARNINGS (LOSS) PER COMMON SHARE

3 Months Ended

Mar. 31, 2016

EARNINGS (LOSS) PER COMMON SHARE

EARNINGS (LOSS) PER COMMON SHARE

NOTE 13. EARNINGS (LOSS) PER COMMON SHARE

The table below is a reconciliation of the numerators and denominators of our basic and diluted earnings (loss) per common share calculations for our continuing operations for three months ended March 31, 2016 and 2015. Net income available (loss attributable) to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

	Net Income Available
	(Loss Attributable)
	to Common		Weighted
	Shareholders		Average Shares	Per-Share
	(Numerator)		(Denominator)	Amount
Three Months Ended March 31, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(55)	98,768	$	(0.56)
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	—		—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(55)	98,768	$	(0.56)
Three Months Ended March 31, 2015
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	46	98,699	$	0.47
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	2,173		(0.01)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	46	100,872	$	0.46

All potentially dilutive securities were excluded from the calculation of diluted loss per share for the three months ended March 31, 2016 because we did not report income from continuing operations available to common shareholders in that period. In circumstances where we do not have income from continuing operations available to common shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive, that is, a loss from continuing operations attributable to common shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the three months ended March 31, 2016, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase of 1,567 shares.

XML

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2016

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

NOTE 14. FAIR VALUE MEASUREMENTS

Our financial assets and liabilities recorded at fair value on a recurring basis primarily relate to investments in available-for-sale securities held by our captive insurance subsidiaries. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are

unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	March 31, 2016		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	60	$	25	$	35	$	—
	$	60	$	25	$	35	$	—

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	December 31, 2015		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	59	$	24	$	35	$	—
	$	59	$	24	$	35	$	—

The fair value of our long-term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At March 31, 2016 and December 31, 2015, the estimated fair value of our long-term debt was approximately 99.1% and 96.2%, respectively, of the carrying value of the debt.

XML

ACQUISITIONS

3 Months Ended

Mar. 31, 2016

ACQUISITIONS

ACQUISITIONS

NOTE 15. ACQUISITIONS

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the three months ended March 31, 2016 are as follows:

Current assets	$	30
Property and equipment		24
Other intangible assets		5
Goodwill		114
Other long-term assets		6
Current liabilities		(9)
Other long-term liabilities		(13)
Redeemable noncontrolling interests in equity of consolidated subsidiaries		(62)
Noncontrolling interests		(37)
Cash paid, net of cash acquired		(29)
Gains on consolidations	$	29

The goodwill generated from these transactions, the majority of which will not be deductible for income tax purposes, was recorded in our Ambulatory Care segment and can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Approximately $5 million in transaction costs related to prospective and closed acquisitions were expensed during the three months ended March 31, 2016, and are included in impairment and restructuring charges, and acquisition-related costs in the accompanying Condensed Consolidated Statement of Operations.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocation over those fair values is recorded as goodwill. We are in process of finalizing the purchase price allocations, including valuations of the acquired property and equipment, other intangible assets, investments in affiliates and noncontrolling interests for our 2016 and 2015 acquisitions; therefore, those purchase price allocations are subject to adjustment once the valuations are completed.

During the three months ended March 31, 2016,  we recognized gains totaling $29 million, associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests.

Pro Forma Information – Unaudited

The following table provides 2016 actual results compared to 2015 pro forma information for Tenet as if the USPI joint venture and Aspen acquisition had occurred at the beginning of the year ended December 31, 2015.

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	5,044	$	4,629
Equity in earnings of unconsolidated affiliates	$	24	$	25
Net income available (loss attributable) to common shareholders	$	(59)	$	28
Earnings (loss) per share available (attributable) to common shareholders	$	(0.60)	$	0.28

XML

SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2016

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 16. SEGMENT INFORMATION

Our business consists of our Hospital Operations and other segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our core business is Hospital Operations and other, which is focused on operating acute care hospitals, ancillary outpatient facilities, freestanding emergency departments, physician practices and health plans. We also own various related healthcare businesses. At March 31, 2016, our subsidiaries operated 84 hospitals, with a total of 21,529 licensed beds, primarily serving urban and suburban communities in 13 states, and six health plans, as well as hospital-based outpatient centers, freestanding emergency departments and freestanding urgent care centers.

Our Ambulatory Care segment is comprised of the operations of our USPI joint venture and our nine Aspen facilities in the United Kingdom. At March 31, 2016, our USPI joint venture had interests in 250 ambulatory surgery centers, 35 urgent care centers, 21 imaging centers and 20 short-stay surgical hospitals in 28 states.

Our Conifer segment provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans. At March 31, 2016, Conifer provided services to more than 800 Tenet and non-Tenet hospitals and other clients nationwide. Our Conifer subsidiary and our Hospital Operations and other segment entered into formal agreements documenting terms and conditions of various services provided by Conifer to Tenet hospitals, as well as certain administrative services provided by our Hospital Operations and other segment to Conifer. The services provided by both parties under these agreements are charged to the other party based on estimated third-party pricing terms.

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:

	March 31,		December 31,
	2016		2015
Assets:
Hospital Operations and other	$	17,131	$	17,353
Ambulatory Care		5,467		5,159
Conifer		1,168		1,170
Total	$	23,766	$	23,682

	Three Months Ended
	March 31,
	2016		2015
Capital expenditures:
Hospital Operations and other	$	191	$	176
Ambulatory Care		12		4
Conifer		5		4
Total	$	208	$	184
Net operating revenues:
Hospital Operations and other	$	4,397	$	4,151
Ambulatory Care		429		91
Conifer
Tenet		167		160
Other customers		218		182
Total Conifer revenues		385		342
Intercompany eliminations		(167)		(160)
Total	$	5,044	$	4,424
Adjusted EBITDA:
Hospital Operations and other	$	414	$	418
Ambulatory Care		136		29
Conifer		63		82
Total	$	613	$	529
Depreciation and amortization:
Hospital Operations and other	$	174	$	192
Ambulatory Care		25		4
Conifer		13		11
Total	$	212	$	207
Adjusted EBITDA	$	613	$	529
Depreciation and amortization		(212)		(207)
Impairment and restructuring charges, and acquisition-related costs		(28)		(29)
Litigation and investigation costs		(173)		(3)
Interest expense		(243)		(199)
Gains on sales, consolidation and deconsolidation of facilities		147		—
Investment earnings		1		—
Net income from continuing operations before income taxes	$	105	$	91

XML

RECENTLY ISSUED ACCOUNTING STANDARDS

3 Months Ended

Mar. 31, 2016

RECENTLY ISSUED ACCOUNTING STANDARDS

RECENTLY ISSUED ACCOUNTING STANDARDS

NOTE 17. RECENT ACCOUNTING STANDARDS

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which affects any entity that enters into a lease (as that term is defined in ASU 2016-02), with some specified scope exceptions. The main difference between the guidance in ASU 2016-02 and previous GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2019.

In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which affects all entities that issue share-based payment awards to their employees. The guidance in ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas of simplification apply only to nonpublic entities. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2017.

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2016

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 18. SUBSEQUENT EVENTS

As previously disclosed, as part of the formation of our USPI joint venture in 2015, we entered into a put/call agreement (the “Put/Call Agreement”) with respect to the equity interests in the joint venture held by our joint venture partners. Each year starting in 2016, our joint venture partners must put to us at least 12.5%, and may put up to 25%, of the equity held by them in the joint venture immediately after the closing. In January 2016, Welsh, Carson, Anderson & Stowe, on behalf of our joint venture partners, delivered a put notice for the minimum number of shares they are required to put to us in 2016 according to the Put/Call Agreement. In April 2016, we paid approximately $127 million to purchase these shares, which increased our ownership interest in the USPI joint venture to approximately 56.3%.

XML

BASIS OF PRESENTATION (Policies)

3 Months Ended

Mar. 31, 2016

BASIS OF PRESENTATION

Basis of Presentation

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company. At March 31, 2016, we operated 84 hospitals, 20 short-stay surgical hospitals, over 475outpatient centers, nine facilities in the United Kingdom and six health plans through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI joint venture”). The results of 142 of these facilities, in which we hold noncontrolling interests, are recorded using the equity method of accounting. Our Conifer Holdings, Inc. (“Conifer”) subsidiary provides healthcare business process services in the areas of revenue cycle management and technology-enabled performance improvement and health management solutions to health systems, as well as individual hospitals, physician practices, self-insured organizations and health plans.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2015 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts).  Certain prior-year amounts have been reclassified to conform to the current-year presentation.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three month period ended March 31, 2016are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the number of covered lives managed by our health plans and the plans’ ability to effectively manage medical costs; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; the number of patients with high-deductible health insurance plans; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

Foreign Currency Transactions and Translations Policy

Translation of Foreign Currencies

The accounts of European Surgical Partners, Limited (“Aspen”) were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities were translated using the current rate of exchange at the balance sheet date. Results of operations were translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

Net Operating Revenues before Provision for Doubtful Accounts

Net Operating Revenues Before Provision for Doubtful Accounts

We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs.

The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:

	Three Months Ended
	March 31,
	2016		2015
General Hospitals:
Medicare	$	859	$	898
Medicaid		373		385
Managed care		2,626		2,405
Indemnity, self-pay and other		437		414
Acute care hospitals — other revenue		7		15
Other:
Other operations		1,118		670
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787

Cash and Cash Equivalents

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $728 million and $356 million at March 31, 2016 and December 31, 2015, respectively. At March 31, 2016 and December 31, 2015, our book overdrafts were approximately $256 million and $301 million, respectively, which were classified as accounts payable.

At March 31, 2016 and December 31, 2015, approximately $175 million and $171 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries and our health plans.

Also at March 31, 2016 and December 31, 2015, we had $110 million and $133 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $63 million and $95 million, respectively, were included in accounts payable.

During the three months ended March 31, 2016 and 2015, we entered into non-cancellable capital leases of approximately $31 million and $33 million, respectively, primarily for buildings and equipment.

Other Intangible Assets

Other Intangible Assets

The following tables provide information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets at March 31, 2016 and December 31, 2015:

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At March 31, 2016:
Capitalized software costs	$	1,495	$	(625)	$	870
Trade names		106		—		106
Contracts		669		(30)		639
Other		117		(46)		71
Total	$	2,387	$	(701)	$	1,686

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At December 31, 2015:
Capitalized software costs	$	1,456	$	(594)	$	862
Trade names		106		—		106
Contracts		653		(26)		627
Other		119		(39)		80
Total	$	2,334	$	(659)	$	1,675

Estimated future amortization of intangibles with finite useful lives at March 31, 2016 is as follows:

			Years Ending December 31,										Later
	Total		2016		2017		2018		2019		2020		Years
Amortization of intangible assets	$	1,207	$	141	$	174	$	146	$	122	$	89	$	535

Investments in Unconsolidated Affiliates

Investments in Unconsolidated Affiliates

We control 213 of the facilities operated by our Ambulatory Care segment and, therefore, consolidate their results (211 are consolidated within our Ambulatory Care segment and two are consolidated within our Hospital Operations and other segment). We account for many of the facilities our Ambulatory Care segment operates (122 of 335 at March 31, 2016) and four of the hospitals our Hospital Operations and other segment operates under the equity method as investments in unconsolidated affiliates and report only our share of net income attributable to the investee as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. Summarized financial information for these equity method investees is included in the following table.

	Three Months Ended
	March 31, 2016
Net operating revenues	$	578
Net income	$	105
Net income attributable to the investees	$	69

XML

BASIS OF PRESENTATION (Tables)

3 Months Ended

Mar. 31, 2016

BASIS OF PRESENTATION

Schedule of sources of net operating revenues before provision for doubtful accounts

	Three Months Ended
	March 31,
	2016		2015
General Hospitals:
Medicare	$	859	$	898
Medicaid		373		385
Managed care		2,626		2,405
Indemnity, self-pay and other		437		414
Acute care hospitals — other revenue		7		15
Other:
Other operations		1,118		670
Net operating revenues before provision for doubtful accounts	$	5,420	$	4,787

Schedule of other intangible assets

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At March 31, 2016:
Capitalized software costs	$	1,495	$	(625)	$	870
Trade names		106		—		106
Contracts		669		(30)		639
Other		117		(46)		71
Total	$	2,387	$	(701)	$	1,686

	Gross
	Carrying		Accumulated		Net Book
	Amount		Amortization		Value
At December 31, 2015:
Capitalized software costs	$	1,456	$	(594)	$	862
Trade names		106		—		106
Contracts		653		(26)		627
Other		119		(39)		80
Total	$	2,334	$	(659)	$	1,675

Schedule of estimated future amortization of intangibles with finite useful lives

			Years Ending December 31,										Later
	Total		2016		2017		2018		2019		2020		Years
Amortization of intangible assets	$	1,207	$	141	$	174	$	146	$	122	$	89	$	535

Schedule of equity method investments

	Three Months Ended
	March 31, 2016
Net operating revenues	$	578
Net income	$	105
Net income attributable to the investees	$	69

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)

3 Months Ended

Mar. 31, 2016

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Schedule Of Components Of Accounts Receivable

	March 31,		December 31,
	2016		2015
Continuing operations:
Patient accounts receivable	$	3,606	$	3,486
Allowance for doubtful accounts		(901)		(887)
Estimated future recoveries from accounts assigned to our Conifer subsidiary		146		144
Net cost reports and settlements payable and valuation allowances		(47)		(42)
		2,804		2,701
Discontinued operations		3		3
Accounts receivable, net	$	2,807	$	2,704

Schedule of estimated costs for charity care and self-pay patients

	Three Months Ended
	March 31,
	2016		2015
Estimated costs for:
Self-pay patients	$	165	$	164
Charity care patients	$	44	$	36
Medicaid DSH and other supplemental revenues	$	227	$	247

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 31, 2016

LONG-TERM DEBT AND LEASE OBLIGATIONS

Summary of long-term debt

	March 31,		December 31,
	2016		2015
Senior notes:
5%, due 2019	$	1,100	$	1,100
51/2%, due 2019		500		500
63/4%, due 2020		300		300
8%, due 2020		750		750
81/8%, due 2022		2,800		2,800
63/4%, due 2023		1,900		1,900
67/8%, due 2031		430		430
Senior secured notes:
61/4%, due 2018		1,041		1,041
43/4%, due 2020		500		500
6%, due 2020		1,800		1,800
Floating % due 2020		900		900
41/2%, due 2021		850		850
43/8%, due 2021		1,050		1,050
Capital leases and mortgage notes		853		852
Unamortized issue costs, note discounts and premium		(252)		(263)
Total long-term debt		14,522		14,510
Less current portion		172		127
Long-term debt, net of current portion	$	14,350	$	14,383

XML

EMPLOYEE BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2016

EMPLOYEE BENEFIT PLANS

Summary of stock option activity

		Weighted Average
		Exercise Price		Aggregate		Weighted Average
	Options	Per Share		Intrinsic Value		Remaining Life
					(In Millions)
Outstanding at December 31, 2015	1,606,842	$	22.87
Granted	—		—
Exercised	(3,950)		4.56
Forfeited/Expired	(29,392)		4.56
Outstanding at March 31, 2016	1,573,500		22.75	$	13	2.9	years
Vested and expected to vest at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years
Exercisable at March 31, 2016	1,573,500	$	22.75	$	13	2.9	years

Summary of information about stock options by range of exercise prices

	Options Outstanding					Options Exercisable
		Weighted Average
	Number of	Remaining		Weighted Average		Number of	Weighted Average
Range of Exercise Prices	Options	Contractual Life		Exercise Price		Options	Exercise Price
$0.00 to $4.569	202,152	2.9	years	$	4.56	202,152	$	4.56
$4.57 to $25.089	910,897	3.6	years		20.99	910,897		20.99
$25.09 to $32.569	182,000	0.9	years		26.40	182,000		26.40
$32.57 to $42.529	278,451	1.8	years		39.31	278,451		39.31
	1,573,500	2.9	years	$	22.75	1,573,500	$	22.75

Summary of restricted stock unit activity

	Restricted Stock	Weighted Average Grant
	Units	Date Fair Value Per Unit
Unvested at December 31, 2015	3,627,232	$	44.69
Granted	1,231,727		31.08
Vested	(1,223,015)		43.68
Forfeited	(23,639)		45.05
Unvested at March 31, 2016	3,612,305	$	40.38

XML

EQUITY (Tables)

3 Months Ended

Mar. 31, 2016

EQUITY

Schedule Of Changes In Consolidated Equity

	Tenet Healthcare Corporation Shareholders’ Equity
						Accumulated
	Common Stock			Additional		Other
	Shares	Issued Par		Paid-in		Comprehensive		Accumulated		Treasury		Noncontrolling
	Outstanding	Amount		Capital		Loss		Deficit		Stock		Interests		Total Equity
Balances at December 31, 2015	98,495	$	7	$	4,815	$	(164)	$	(1,550)	$	(2,417)	$	267	$	958
Net income  (loss)	—		—		—		—		(59)		—		13		(46)
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		10		10
Other comprehensive income	—		—		—		4		—		—		—		4
Purchases (sales) of businesses and noncontrolling interests	—		—		(7)		—		—		—		21		14
Stock-based compensation expense, tax benefit and issuance of common stock	773		—		(4)		—		—		—		—		(4)
Balances at March 31, 2016	99,268	$	7	$	4,804	$	(160)	$	(1,609)	$	(2,417)	$	301	$	926
Balances at December 31, 2014	98,382	$	7	$	4,614	$	(182)	$	(1,410)	$	(2,378)	$	134	$	785
Net income	—		—		—		—		47		—		8		55
Distributions paid to noncontrolling interests	—		—		—		—		—		—		(10)		(10)
Contributions from noncontrolling interests	—		—		—		—		—		—		1		1
Other comprehensive income	—		—		—		3		—		—		—		3
Purchases (sales) of businesses and noncontrolling interests	—		—		129		—		—		—		—		129
Stock-based compensation expense and issuance of common stock	782		—		8		—		—		1		—		9
Balance at March 31, 2015	99,164	$	7	$	4,751	$	(179)	$	(1,363)	$	(2,377)	$	133	$	972

XML

CLAIMS AND LAWSUITS (Tables)

3 Months Ended

Mar. 31, 2016

CLAIMS AND LAWSUITS

Reconciliations Of Legal Settlements And Related Costs

	Balances at		Litigation and				Balances at
	Beginning		Investigation		Cash		End of
	of Period		Costs		Payments		Period
Three Months Ended March 31, 2016
Continuing operations	$	299	$	173	$	(45)	$	427
Discontinued operations		—		—		—		—
	$	299	$	173	$	(45)	$	427
Three Months Ended March 31, 2015
Continuing operations	$	73	$	3	$	(15)	$	61
Discontinued operations		10		(3)		—		7
	$	83	$	—	$	(15)	$	68

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)

3 Months Ended

Mar. 31, 2016

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

Schedule of changes in redeemable noncontrolling interests in equity of consolidated subsidiaries

	Three Months Ended
	March 31,
	2016		2015
Balances at beginning of period	$	2,266	$	401
Net income		80		21
Distributions paid to noncontrolling interests		(34)		(1)
Contributions from noncontrolling interests		6		1
Purchases and sales of businesses and noncontrolling interests, net		63		(214)
Balances at end of period	$	2,381	$	208

XML

EARNINGS (LOSS) PER COMMON SHARE (Tables)

3 Months Ended

Mar. 31, 2016

EARNINGS (LOSS) PER COMMON SHARE

Schedule of reconciliation of numerators and denominators of our basic and diluted loss per common share

	Net Income Available
	(Loss Attributable)
	to Common		Weighted
	Shareholders		Average Shares	Per-Share
	(Numerator)		(Denominator)	Amount
Three Months Ended March 31, 2016
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$	(55)	98,768	$	(0.56)
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	—		—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$	(55)	98,768	$	(0.56)
Three Months Ended March 31, 2015
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	46	98,699	$	0.47
Effect of dilutive stock options, restricted stock units and deferred compensation units		—	2,173		(0.01)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	46	100,872	$	0.46

XML

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2016

FAIR VALUE MEASUREMENTS

Schedule of assets and liabilities measured at fair value on a recurring basis

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	March 31, 2016		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	60	$	25	$	35	$	—
	$	60	$	25	$	35	$	—

			Quoted Prices
			in Active				Significant
			Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
Investments	December 31, 2015		(Level 1)		(Level 2)		(Level 3)
Marketable debt securities — noncurrent	$	59	$	24	$	35	$	—
	$	59	$	24	$	35	$	—

XML

ACQUISITIONS (Tables)

3 Months Ended

Mar. 31, 2016

Business Acquisition

Schedule of pro forma financial information as if USPI joint venture and Aspen acquisition had occurred at the beginning of the year

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	5,044	$	4,629
Equity in earnings of unconsolidated affiliates	$	24	$	25
Net income available (loss attributable) to common shareholders	$	(59)	$	28
Earnings (loss) per share available (attributable) to common shareholders	$	(0.60)	$	0.28

Series of individual business acquisitions

Business Acquisition

Schedule of Preliminary purchase price allocation

Current assets	$	30
Property and equipment		24
Other intangible assets		5
Goodwill		114
Other long-term assets		6
Current liabilities		(9)
Other long-term liabilities		(13)
Redeemable noncontrolling interests in equity of consolidated subsidiaries		(62)
Noncontrolling interests		(37)
Cash paid, net of cash acquired		(29)
Gains on consolidations	$	29

XML

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2016

SEGMENT INFORMATION

Reconciliation of assets by reportable segment to consolidated assets

	March 31,		December 31,
	2016		2015
Assets:
Hospital Operations and other	$	17,131	$	17,353
Ambulatory Care		5,467		5,159
Conifer		1,168		1,170
Total	$	23,766	$	23,682

Reconciliation of other significant reconciling items from segments to consolidated

	Three Months Ended
	March 31,
	2016		2015
Capital expenditures:
Hospital Operations and other	$	191	$	176
Ambulatory Care		12		4
Conifer		5		4
Total	$	208	$	184
Net operating revenues:
Hospital Operations and other	$	4,397	$	4,151
Ambulatory Care		429		91
Conifer
Tenet		167		160
Other customers		218		182
Total Conifer revenues		385		342
Intercompany eliminations		(167)		(160)
Total	$	5,044	$	4,424
Adjusted EBITDA:
Hospital Operations and other	$	414	$	418
Ambulatory Care		136		29
Conifer		63		82
Total	$	613	$	529
Depreciation and amortization:
Hospital Operations and other	$	174	$	192
Ambulatory Care		25		4
Conifer		13		11
Total	$	212	$	207
Adjusted EBITDA	$	613	$	529
Depreciation and amortization		(212)		(207)
Impairment and restructuring charges, and acquisition-related costs		(28)		(29)
Litigation and investigation costs		(173)		(3)
Interest expense		(243)		(199)
Gains on sales, consolidation and deconsolidation of facilities		147		—
Investment earnings		1		—
Net income from continuing operations before income taxes	$	105	$	91

XML

BASIS OF PRESENTATION (Details)	3 Months Ended
	Mar. 31, 2016 plan Institution
Business Acquisition
Number of acute care hospitals operated by subsidiaries	84
Number of short-stay surgical hospitals	20
Number of outpatient centers	475
Number of outpatient centers recorded using equity method	142
Number of facilities owned by subsidiaries	9
Number of health plans | plan	6
United Surgical Partners International
Business Acquisition
Number of short-stay surgical hospitals	20

XML

BASIS OF PRESENTATION - Revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	$ 5,420	$ 4,787
Medicare
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	859	898
Medicaid
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	373	385
Managed care
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	2,626	2,405
Indemnity, self-pay and other
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	437	414
Acute care hospitals - other revenue
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	7	15
Other operations
Supplemental payments and net operating revenues
Net operating revenues before provision for doubtful accounts	$ 1,118	$ 670

XML

BASIS OF PRESENTATION - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents
Cash and cash equivalents	$ 728	$ 185	$ 356	$ 193
Accrued property and equipment purchases for items received but not yet paid	110		133
Non-cancellable capital leases primarily for buildings and equipment	31	$ 33
Accounts payable
Cash and Cash Equivalents
Book overdrafts classified as accounts payable	256		301
Accrued property and equipment purchases for items received but not yet paid	63		95
Captive insurance subsidiaries
Cash and Cash Equivalents
Cash and cash equivalents	$ 175		$ 171

XML

BASIS OF PRESENTATION - Intangible Assets Summary (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Other intangible assets
Gross Carrying Amount	$ 2,387	$ 2,334
Accumulated Amortization	(701)	(659)
Net Book Value	1,686	1,675
Capitalized software costs
Other intangible assets
Gross Carrying Amount	1,495	1,456
Accumulated Amortization	(625)	(594)
Net Book Value	870	862
Trade names
Other intangible assets
Gross Carrying Amount	106	106
Net Book Value	106	106
Contracts
Other intangible assets
Gross Carrying Amount	669	653
Accumulated Amortization	(30)	(26)
Net Book Value	639	627
Other
Other intangible assets
Gross Carrying Amount	117	119
Accumulated Amortization	(46)	(39)
Net Book Value	$ 71	$ 80

XML

BASIS OF PRESENTATION - Amortization of Intangible Assets (Details) $ in Millions	Mar. 31, 2016 USD ($)
Estimated future amortization of intangibles with finite useful lives
Total	$ 1,207
2016	141
2017	174
2018	146
2019	122
2020	89
Later Years	$ 535

XML

BASIS OF PRESENTATION - Investments in Unconsolidated Affiliates (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) Institution
Schedule of Equity Method Investments [Line Items]
Net operating revenues | $	$ 578
Net income | $	105
Net income attributable to the investee | $	$ 69
Number of outpatient centers	475
Number of outpatient centers recorded using equity method	142
Number of outpatient centers recorded not using equity method	213
Ambulatory Care
Schedule of Equity Method Investments [Line Items]
Number of outpatient centers	335
Number of outpatient centers recorded using equity method	122
Number of outpatient centers recorded not using equity method	211
Hospital operations and other
Schedule of Equity Method Investments [Line Items]
Number of hospitals recorded using equity method	4
Number of outpatient centers recorded not using equity method	2

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Components (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Accounts receivable and allowance for doubtful accounts
Accounts receivable, net	$ 2,807	$ 2,704
Continuing operations
Accounts receivable and allowance for doubtful accounts
Patient accounts receivable	3,606	3,486
Allowance for doubtful accounts	(901)	(887)
Estimated future recoveries from accounts assigned to our Conifer subsidiary	146	144
Net cost reports and settlements payable and valuation allowances	(47)	(42)
Accounts receivable, net	2,804	2,701
Discontinued operations
Accounts receivable and allowance for doubtful accounts
Accounts receivable, net	$ 3	$ 3

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Allowance (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Accounts receivable and allowance for doubtful accounts
Allowance for doubtful accounts as a percent of patients accounts receivable	25.00%		25.40%
Self-Pay Patients
Accounts receivable and allowance for doubtful accounts
Allowance for doubtful accounts as a percent of patients accounts receivable	81.20%		80.60%
Estimated costs of caring	$ 165	$ 164
Managed Care Patients
Accounts receivable and allowance for doubtful accounts
Allowance for doubtful accounts as a percent of patients accounts receivable	8.40%		7.50%
Charity Care Patients
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	$ 44	36
Medicai DSH and other supplemental revenues
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	$ 227	$ 247

XML

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS - Other Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Accounts receivable and allowance for doubtful accounts
Receivables	$ 2,807	$ 2,704
Payables	1,228	1,380
California's Provider Fee Program | Other current assets
Accounts receivable and allowance for doubtful accounts
Receivables	450	387
California's Provider Fee Program | Other current liabilities
Accounts receivable and allowance for doubtful accounts
Payables	$ 174	$ 139

XML

ASSETS AND LIABILITIES HELD FOR SALE (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Current Assets and Liabilities Held for Sale
Assets held for sale	$ 2	$ 550
Proceeds from sales of facilities and other assets	573
Net receivables	2,807	2,704
Liabilities held for sale		101
Impairment charges	2
Georgia Facilities | Disposal Group, Held-for-sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Assets held for sale		549
Liabilities held for sale		$ 101
Georgia Facilities | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Current Assets and Liabilities Held for Sale
Proceeds from sales of facilities and other assets	575
Net receivables	141
Gain on sale	$ 113

XML

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) segment	Mar. 31, 2015 USD ($)
IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS
Net impairment and restructuring charges and acquisition-related costs	$ 28	$ 29
Impairment charges	2
Employee severance costs	10	6
Restructuring costs	1	3
Lease termination costs	1
Acquisition costs	14	20
Acquisition-related transaction costs	5	7
Acquisition integration charges	$ 9	$ 13
Number of continuing operating segments | segment	3

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS - Schedule of Debt (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
LONG-TERM DEBT AND LEASE OBLIGATIONS
Capital leases and mortgage notes	$ 853	$ 852
Unamortized note discounts and premium	(252)	(263)
Total long-term debt	14,522	14,510
Less current portion	172	127
Long-term debt, net of current portion	$ 14,350	$ 14,383
5%, due 2019
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.00%	5.00%
Carrying amount	$ 1,100	$ 1,100
5 1/2%, due 2019
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	5.50%	5.50%
Carrying amount	$ 500	$ 500
6 3/4%, due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.75%	6.75%
Carrying amount	$ 300	$ 300
8%, due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	8.00%	8.00%
Carrying amount	$ 750	$ 750
8 1/8%, due 2022
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	8.125%	8.125%
Carrying amount	$ 2,800	$ 2,800
6 3/4%, due 2023
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.75%	6.75%
Carrying amount	$ 1,900	$ 1,900
6 7/8%, due 2031
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.875%	6.875%
Carrying amount	$ 430	$ 430
6 1/4%, due 2018
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.25%	6.25%
Carrying amount	$ 1,041	$ 1,041
4 3/4%, due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.75%	4.75%
Carrying amount	$ 500	$ 500
6%, due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	6.00%	6.00%
Carrying amount	$ 1,800	$ 1,800
Floating % due 2020
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 900	$ 900
4 1/2%, due 2021
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.50%	4.50%
Carrying amount	$ 850	$ 850
4 3/8%, due 2021
LONG-TERM DEBT AND LEASE OBLIGATIONS
Interest rate, stated percentage	4.375%	4.375%
Carrying amount	$ 1,050	$ 1,050

XML

LONG-TERM DEBT AND LEASE OBLIGATIONS - Credit Agreement and Letter of Credit Facility (Details)	3 Months Ended
	Mar. 31, 2016 USD ($)	Mar. 07, 2014 USD ($)
Credit Agreement
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity	$ 1,000,000,000
Line of credit facility, subfacility maximum available capacity	300,000,000
Borrowings outstanding	0
Standby letters of credit outstanding	4,000,000
Amount available for borrowing under revolving credit facility	$ 996,000,000
Credit Agreement | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (as a percent)	0.25%
Credit Agreement | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (as a percent)	0.375%
Credit Agreement | Base rate | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (as a percent)	0.25%
Credit Agreement | Base rate | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (as a percent)	0.75%
Credit Agreement | LIBOR | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (as a percent)	1.25%
Credit Agreement | LIBOR | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (as a percent)	1.75%
Letter of Credit Facility
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity		$ 180,000,000
Unused commitment fee (as a percent)	0.50%
Standby letters of credit outstanding	$ 139,000,000
Borrowing capacity after increase subject to certain conditions		$ 200,000,000
Secured debt to EBITDA ratio	3.00
Issuance fee (percentage)	1.875%
Issuance fee, based on face amount (percentage)	0.125%
Letter of Credit Facility | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Number of business days after notice, for reimbursement of amount drawn.	3 days
Unused commitment fee after step down	0.375%
Letter of Credit Facility | Base rate
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (as a percent)	0.875%

XML

GUARANTEES (Details) $ in Millions	Mar. 31, 2016 USD ($)
Income and Revenue Collection Guarantee
GUARANTEES
Maximum potential amount of future payments under guarantees	$ 89
Income and Revenue Collection Guarantee | Other current liabilities
GUARANTEES
Liability for the fair value of guarantees	75
Guaranteed Investees Of Third Parties
GUARANTEES
Liability for the fair value of guarantees	35
Guaranteed Investees Of Third Parties | Other current liabilities
GUARANTEES
Guarantee obligations for consolidated subsidiaries	$ 17

XML

EMPLOYEE BENEFIT PLANS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
EMPLOYEE BENEFIT PLANS
Stock-based compensation costs, pretax	$ 14	$ 18
2008 Stock Incentive Plan
EMPLOYEE BENEFIT PLANS
Shares available for issuance under the plan	1,700,000
2008 Stock Incentive Plan | Stock Options
EMPLOYEE BENEFIT PLANS
Expiration period from the date of grant	10 years
Portion of awards vesting on each of the first three anniversary dates of the grant (as a percent)	33.30%
Vesting period	3 years
2008 Stock Incentive Plan | Restricted Stock Units
EMPLOYEE BENEFIT PLANS
Contractual right to receive shares of common stock for a stock based award	1
Portion of awards vesting on each of the first three anniversary dates of the grant (as a percent)	33.30%
Vesting period	3 years

XML

EMPLOYEE BENEFIT PLANS - Stock Options (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Stock option activity
Stock-Based Compensation Expense	$ 14,000,000	$ 18,000,000
Stock Options
Stock option activity
Outstanding at the beginning of the period (in shares)	1,606,842
Granted (in shares)		0
Exercised (in shares)	(3,950)	(77,658)
Forfeited/Expired (in shares)	(29,392)
Outstanding at the end of the period (in shares)	1,573,500		1,606,842
Vested and expected to vest at the end of the period (in shares)	1,573,500
Exercisable at the end of the period (in shares)	1,573,500
Weighted Average Exercise Price Per Share
Outstanding at the beginning of the period (in dollars per share)	$ 22.87
Exercised (in dollars per share)	4.56
Forfeited/Expired (in dollars per share)	4.56
Outstanding at the end of the period (in dollars per share)	22.75		$ 22.87
Vested and expected to vest at the end of the period (in dollars per share)	22.75
Exercisable at the end of the period (in dollars per share)	$ 22.75
Aggregate Intrinsic Value
Outstanding at the end of the period	$ 13,000,000
Vested and expected to vest at the end of the period	13,000,000
Exercisable at the end of the period	$ 13,000,000
Weighted Average Remaining Life
Outstanding at the end of the period	2 years 10 months 24 days		3 years 10 months 24 days
Vested and expected to vest at the end of the period	3 years 10 months 24 days
Exercisable at the end of the period	3 years 8 months 12 days
Other Disclosures
Aggregate Intrinsic value of awards exercised	$ 1,000,000	$ 1,000,000
Unrecognized compensation costs		$ 0

XML

EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details) - Stock Options	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Options Outstanding
Number of Options Outstanding (in shares) | shares	1,573,500
Weighted Average Remaining Contractual life	2 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 22.75
Options Exercisable
Number of Options Exercisable (in shares) | shares	1,573,500
Weighted Average Exercise Price (in dollars per share)	$ 22.75
Range of Exercise Prices, $0.00 to $4.569
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	0.00
Exercise price per share, high end of the range (in dollars per share)	$ 4.569
Options Outstanding
Number of Options Outstanding (in shares) | shares	202,152
Weighted Average Remaining Contractual life	2 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 4.56
Options Exercisable
Number of Options Exercisable (in shares) | shares	202,152
Weighted Average Exercise Price (in dollars per share)	$ 4.56
Range of Exercise Prices, $4.57 to $25.089
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	4.57
Exercise price per share, high end of the range (in dollars per share)	$ 25.089
Options Outstanding
Number of Options Outstanding (in shares) | shares	910,897
Weighted Average Remaining Contractual life	3 years 7 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 20.99
Options Exercisable
Number of Options Exercisable (in shares) | shares	910,897
Weighted Average Exercise Price (in dollars per share)	$ 20.99
Range of Exercise Prices, $25.09 to $32.569
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	25.09
Exercise price per share, high end of the range (in dollars per share)	$ 32.569
Options Outstanding
Number of Options Outstanding (in shares) | shares	182,000
Weighted Average Remaining Contractual life	10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 26.40
Options Exercisable
Number of Options Exercisable (in shares) | shares	182,000
Weighted Average Exercise Price (in dollars per share)	$ 26.40
Range of Exercise Prices, $32.57 to $42.529
Summary information about outstanding stock options
Exercise price per share, low end of the range (in dollars per share)	32.57
Exercise price per share, high end of the range (in dollars per share)	$ 42.529
Options Outstanding
Number of Options Outstanding (in shares) | shares	278,451
Weighted Average Remaining Contractual life	1 year 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 39.31
Options Exercisable
Number of Options Exercisable (in shares) | shares	278,451
Weighted Average Exercise Price (in dollars per share)	$ 39.31

XML

EMPLOYEE BENEFIT PLANS - Restricted Stock (Details) - Restricted Stock Units $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2016 director $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares
Restricted stock unit activity
Unvested at the beginning of the period (in shares)	3,627,232	3,627,232
Granted (in shares)		1,231,727
Vested (in shares)		(1,223,015)
Forfeited (in shares)		(23,639)
Unvested at the end of the period (in shares)		3,612,305
Weighted Average Grant Date Fair Value Per Unit
Unvested at the beginning of the period (in dollars per share) | $ / shares	$ 44.69	$ 44.69
Granted (in dollars per share) | $ / shares		31.08
Vested (in dollars per share) | $ / shares		43.68
Forfeited (in dollars per share) | $ / shares		45.05
Unvested at the end of the period (in dollars per share) | $ / shares		$ 40.38
Other Disclosures
Unrecognized compensation costs | $		$ 117
Period for recognition of unrecognized compensation costs		2 years 3 months 18 days
Time-vesting
Restricted stock unit activity
Granted (in shares)		474,052
Other Disclosures
Restricted stock that will vest and be settled over a three-year period from the grant date (in shares)		458,379
Restricted stock that will vest and be settled on the third anniversary of the grant date (in shares)		15,673
Vesting period		3 years
Time-vesting | Director
Other Disclosures
Initial grant received (in shares)	5,084
Pro-rated annual grant (in shares)	5,614
New directors | director	2
Performance-based vesting
Restricted stock unit activity
Granted (in shares)		291,540
Performance-based vesting | Minimum
Other Disclosures
Awards vesting (as a percent)		0.00%
Performance-based vesting | Maximum
Other Disclosures
Awards vesting (as a percent)		200.00%
Performance-based vesting | Senior Officers
Restricted stock unit activity
Granted (in shares)		455,437
Other Disclosures
Term for achievement of specified performance goal		3 years

XML

EQUITY - Changes in Shareholders' Equity (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Changes in Shareholders' Equity
Balances	$ 958	$ 785
Net income (loss)	(46)	55
Distributions paid to noncontrolling interests	(10)	(10)
Contributions from noncontrolling interests	10	1
Other comprehensive income	4	3
Purchases (sales) of businesses and noncontrolling interests	14	129
Stock-based compensation expense and issuance of common stock	(4)	9
Balances	926	972
Common Stock
Changes in Shareholders' Equity
Balances	$ 7	$ 7
Balances (in shares)	98,495	98,382
Stock-based compensation expense and issuance of common stock (in shares)	773	782
Balances	$ 7	$ 7
Balances (in shares)	99,268	99,164
Additional Paid-in Capital
Changes in Shareholders' Equity
Balances	$ 4,815	$ 4,614
Purchases (sales) of businesses and noncontrolling interests	(7)	129
Stock-based compensation expense and issuance of common stock	(4)	8
Balances	4,804	4,751
Accumulated Other Comprehensive Loss
Changes in Shareholders' Equity
Balances	(164)	(182)
Other comprehensive income	4	3
Balances	(160)	(179)
Accumulated Deficit
Changes in Shareholders' Equity
Balances	(1,550)	(1,410)
Net income (loss)	(59)	47
Balances	(1,609)	(1,363)
Treasury Stock
Changes in Shareholders' Equity
Balances	(2,417)	(2,378)
Stock-based compensation expense and issuance of common stock		1
Balances	(2,417)	(2,377)
Noncontrolling Interests
Changes in Shareholders' Equity
Balances	267	134
Net income (loss)	13	8
Distributions paid to noncontrolling interests	(10)	(10)
Contributions from noncontrolling interests	10	1
Purchases (sales) of businesses and noncontrolling interests	21
Balances	$ 301	$ 133

XML

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Other operating expense, net
Insurance coverage
Malpractice expense	$ 93	$ 89
Professional and General Liability Insurance
Insurance coverage
Self insurance reserve	$ 784		$ 755
Loss contingency discount rate, maturity rate period	7 years		7 years
Risk-free discount rate (as a percent)	1.54%		2.09%

XML

CLAIMS AND LAWSUITS (Details)	1 Months Ended	3 Months Ended
	Jun. 30, 2006 defendant	Mar. 31, 2016 USD ($) defendant item Institution	Dec. 31, 2015 USD ($)
Loss Contingencies
Reimbursement times | item		3
Clinica de la Mama Investigations and Qui Tam Action
Loss Contingencies
Number of defendants | defendant		4
Number of hospitals with sold operating assets | Institution		3
Litigation reserve | $		$ 407,000,000	$ 238,000,000
Clinica de la Mama Investigations and Qui Tam Action | Minimum
Loss Contingencies
Number of hospitals that could enter into a guilty plea | Institution		1
Antitrust Class Action Lawsuit
Loss Contingencies
Number of defendants | defendant	3

XML

CLAIMS AND LAWSUITS - Reconciliations (Details) - Claims, lawsuits, and regulatory proceedings - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Loss Contingencies
Litigation reserve, Balances at Beginning of Period	$ 299	$ 83
Litigation and Investigation costs	173
Cash Payments	(45)	(15)
Litigation reserve, Balances at End of Period	427	68
Continuing operations
Loss Contingencies
Litigation reserve, Balances at Beginning of Period	299	73
Litigation and Investigation costs	173	3
Cash Payments	(45)	(15)
Litigation reserve, Balances at End of Period	$ 427	61
Discontinued operations
Loss Contingencies
Litigation reserve, Balances at Beginning of Period		10
Litigation and Investigation costs		(3)
Litigation reserve, Balances at End of Period		$ 7

XML

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries
Distributions paid to noncontrolling interests	$ (10)	$ (10)
Contributions from noncontrolling interests	10	1
Redeemable noncontrolling interests
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries
Balances at beginning of period	2,266	401
Net income	80	21
Distributions paid to noncontrolling interests	(34)	(1)
Contributions from noncontrolling interests	6	1
Purchases and sales of businesses and noncontrolling interests, net	63	(214)
Balances at end of period	$ 2,381	$ 208

XML

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Taxes
Income tax expenses	$ 67	$ 16
State income tax expense	13
Nondeductible goodwill	29
Nontaxable gains	17
Tax benefits related to net income of noncontrolling interests	21
Continued operations pre-tax earnings	105	$ 91
Reduction in estimated liabilities for uncertain tax positions	3
Unrecognized tax benefits	37
Unrecognized tax benefits which, if recognized, would impact effective tax rate	34
Nondeductible litigation	26
Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months	6
Continuing operations
Income Taxes
Interest and penalties related to accrued liabilities for uncertain tax positions, recognized	$ 5

XML

EARNINGS (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Income Available (Loss Attributable) to Common Shareholders (Numerator)
Net income attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$ (55)	$ 46
Effect of dilutive stock options, restricted stock units, and deferred compensation units
Net income attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$ (55)	$ 46
Weighted Average Shares (Denominator)
Net income attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	98,768	98,699
Effect of dilutive stock options, restricted stock units and deferred compensation units (in weighted average shares)		2,173
Net income attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	98,768	100,872
Per-Share Amount
Net income attributable to Tenet Healthcare Corporation common shareholders for basic loss per share	$ (0.56)	$ 0.47
Effect of dilutive stock options, restricted stock units, and deferred compensation units (Per-Share)		(0.01)
Net income attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share	$ (0.56)	$ 0.46

XML

EARNINGS (LOSS) PER COMMON SHARE - Antidilutive securities (Details)	3 Months Ended
	Mar. 31, 2016 shares
Employee stock options, restricted stock units and deferred compensation units
Antidilutive securities
Anti-dilutive securities excluded from computation of earnings per share	1,567

XML

FAIR VALUE MEASUREMENTS (Details) - Recurring basis - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities-noncurrent	$ 60	$ 59
Investments	60	59
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities-noncurrent	25	24
Investments	$ 25	$ 24
Estimated fair value of the long-term debt instrument as a percentage of carrying value	99.10%	96.20%
Significant Other Observable Inputs (Level 2)
Fair value of assets and liabilities measured on recurring basis
Marketable debt securities-noncurrent	$ 35	$ 35
Investments	$ 35	$ 35

XML

ACQUISITIONS - Purchase Price Allocation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Preliminary purchase price allocations
Goodwill	$ 7,122	$ 6,970
Series of individual business acquisitions
Preliminary purchase price allocations
Current assets	30
Property and equipment	24
Other intangible assets	5
Goodwill	114
Other long-term assets	6
Current liabilities	(9)
Other long-term liabilities	(13)
Redeemable noncontrolling interests in equity of consolidated subsidiaries	(62)
Noncontrolling interests	(37)
Net cash paid	(29)
Gain on consolidations	29
Transaction costs related to prospective and closed acquisitions	$ 5

XML

ACQUISITIONS - Pro Forma (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Pro Forma Information - Unaudited
Net operating revenues	$ 5,044	$ 4,629
Equity in earnings of unconsolidated affiliates	24	4
Net income attributable (loss attributable) to common shareholders	$ (59)	$ 28
Net earnings (loss) per share available (attributable) to common shareholders	$ (0.60)	$ 0.28
Pro Forma
Pro Forma Information - Unaudited
Equity in earnings of unconsolidated affiliates	$ 24	$ 25

XML

SEGMENT INFORMATION - General Information and Customer Concentration (Details)	3 Months Ended
	Mar. 31, 2016 state item plan Institution
SEGMENT INFORMATION
Number of hospitals owned by subsidiaries	84
Number of facilities owned by subsidiaries	9
Number of short-stay surgical hospitals	20
Number of licensed beds in hospitals operated by subsidiaries | item	21,529
Number of states where operations occur | state	13
Number of provider-based outpatient centers operated by subsidiaries	475
Number of health plans | plan	6
United Surgical Partners International
SEGMENT INFORMATION
Number of short-stay surgical hospitals	20
Number of ambulatory surgery centers	250
Number of diagnostic imaging centers	21
Number of states where operations occur | state	28
Number of urgent care centers	35
European Surgical Partners Ltd
SEGMENT INFORMATION
Number of facilities owned by subsidiaries	9
Minimum | Conifer
SEGMENT INFORMATION
Number of Tenet and non-Tenet Hospitals and other health care organizations to which Conifer provided revenue cycle services	800

XML

SEGMENT INFORMATION - Reconciling Items (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
SEGMENT INFORMATION
Assets	$ 23,766		$ 23,682
Capital expenditures:	208	$ 184
Net operating revenues	5,044	4,424
Adjusted EBITDA	613	529
Depreciation and amortization	212	207
Adjusted EBITDA and other reconciling items
Adjusted EBITDA	613	529
Depreciation and amortization	(212)	(207)
Impairment and restructuring charges, and acquisition-related costs	(28)	(29)
Litigation and investigation costs	(173)	(3)
Interest expense	(243)	(199)
Gains on sales, consolidation and deconsolidation of facilities	147
Investment earnings	1
Net income from continuing operations, before income taxes	105	91
Hospital operations and other
SEGMENT INFORMATION
Assets	17,131		17,353
Conifer
SEGMENT INFORMATION
Assets	1,168		1,170
Ambulatory Care
SEGMENT INFORMATION
Assets	5,467		$ 5,159
Operating segments | Hospital operations and other
SEGMENT INFORMATION
Capital expenditures:	191	176
Net operating revenues	4,397	4,151
Adjusted EBITDA	414	418
Depreciation and amortization	174	192
Adjusted EBITDA and other reconciling items
Adjusted EBITDA	414	418
Depreciation and amortization	(174)	(192)
Operating segments | Conifer
SEGMENT INFORMATION
Capital expenditures:	5	4
Net operating revenues	385	342
Adjusted EBITDA	63	82
Depreciation and amortization	13	11
Adjusted EBITDA and other reconciling items
Adjusted EBITDA	63	82
Depreciation and amortization	(13)	(11)
Operating segments | Conifer | Tenet
SEGMENT INFORMATION
Net operating revenues	167	160
Operating segments | Conifer | Other customers
SEGMENT INFORMATION
Net operating revenues	218	182
Operating segments | Ambulatory Care
SEGMENT INFORMATION
Capital expenditures:	12	4
Net operating revenues	429	91
Adjusted EBITDA	136	29
Depreciation and amortization	25	4
Adjusted EBITDA and other reconciling items
Adjusted EBITDA	136	29
Depreciation and amortization	(25)	(4)
Intercompany eliminations
SEGMENT INFORMATION
Net operating revenues	$ (167)	$ (160)

XML

SUBSEQUENT EVENTS (Details) - United Surgical Partners International - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2016	Mar. 31, 2016
Minimum | Put Option
Subsequent events
Equity necessary for joint venture (as a percent)		12.50%
Maximum | Put Option
Subsequent events
Equity necessary for joint venture (as a percent)		25.00%
Subsequent event
Subsequent events
Amount paid for repurchase	$ 127
Ownership interest (as a percent)	56.30%